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About the Health Information and Quality Authority  
 
The Health Information and Quality Authority is the independent Authority which has 
been established to drive continuous improvement in Ireland’s health and social care 
services. The Authority was established as part of the Government’s overall Health 
Service Reform Programme. 
 
The Authority’s mandate extends across the quality and safety of the public, 
private (within its social care function) and voluntary sectors. Reporting directly to 
the Minister for Health and Children, the Health Information and Quality Authority 
has statutory responsibility for: 
 
Setting Standards for Health and Social Services — Developing person centred 
standards, based on evidence and best international practice, for health and social 
care services in Ireland (except mental health services) 
 
Social Services Inspectorate — Registration and inspection of residential 
homes for children, older people and people with disabilities. Inspecting children 
detention schools and foster care services. Monitoring day and pre-school facilities1 
 
Monitoring Healthcare Quality — Monitoring standards of quality and safety in 
our health services and investigating as necessary serious concerns about the health 
and welfare of service users 
 
Health Technology Assessment — Ensuring the best outcome for the 
service user by evaluating the clinical and economic effectiveness of drugs, 
equipment, diagnostic techniques and health promotion activities 
 
Health Information — Advising on the collection and sharing of 
information across the services, evaluating information and publishing 
information about the delivery and performance of Ireland’s health and 
social care services 
 
 
 
 
 
 
 
 
 
                                                 
1 Not all parts of the relevant legislation, the Health Act 2007, have yet been commenced.  
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Foreword 
 
The Health Information and Quality Authority has a statutory remit to evaluate the 
clinical and cost-effectiveness of health technologies and provide advice arising out 
of the evaluation to the Minister for Health and Children and the Health Service 
Executive (HSE). The primary audience for health technology assessments (HTAs) 
conducted by the Authority is therefore decision makers within the publicly-funded 
healthcare system. It is recognised that the findings of any such HTA may also have 
implications for other key stakeholders in the Irish healthcare system. These include 
patient groups, the general public, clinicians, other healthcare providers, academic 
groups and the manufacturing industry. 
  
The HTA guidelines provide an overview of the principles and methods used in 
assessing health technologies. They are intended as a guide for all those who are 
involved in the conduct or use of HTA in Ireland. The purpose of the guidelines is to 
promote the production of assessments that are timely, reliable, consistent and 
relevant to the needs of decision makers and key stakeholders in Ireland. 
 
The HTA guidelines will comprise several sections including guidance on economic 
evaluation, budget impact analysis, social, ethical and organisational aspects of HTA 
and recommended reporting formats. Each of these sections is important. Rather 
than delay publication of the guidelines until all sections were complete, it was 
considered prudent to develop the sections of the guidelines as stand alone 
documents, commencing with the economic guidelines. 
 
This document, Guidelines for the Economic Evaluation of Health Technologies in 
Ireland represents the first section of the HTA guidelines. They are limited to the 
methodological guidance on the conduct of economic assessments. They are 
intended to replace the Irish Healthcare Technology Assessment Guidelines, 2000 
and will be reviewed and revised as necessary. 
 
The purpose of these economic guidelines is to assist those conducting or using 
economic evaluations as part of HTA in Ireland.  They are intended to inform 
economic evaluations conducted by, or on behalf of the Health Information and 
Quality Authority, the National Centre for Pharmacoeconomics, the Department of 
Health and Children and the Health Service Executive (HSE), to include health 
technology suppliers preparing applications for reimbursement. These guidelines 
specify the preferred methods or ‘reference case’ that should be used in the primary 
analysis. For ease of use, guideline statements that summarise key points are 
included prior to each section in italics.  
 
The economic guidelines have been developed in consultation with the Scientific 
Advisory Group of the Authority. Providing broad representation from key 
stakeholders in healthcare in Ireland, this group includes methodological experts 
from the field of HTA. The Authority would like to thank the members of the 
Scientific Advisory Group and its Chairperson, Dr Michael Barry from the National 
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Centre for Pharmacoeconomics, and all who have contributed to the production of 
these guidelines.  
 
Dr Máirín Ryan 
Director of Health Technology Assessment 
Health Information and Quality Authority 
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Process and Acknowledgements 
 
The economic guidelines have been developed by the Authority with technical input 
from the National Centre for Pharmacoeconomics and in consultation with its 
Scientific Advisory Group (SAG). Providing broad representation from key 
stakeholders in Irish healthcare, this group includes methodological experts from the 
field of health technology assessment (HTA). The group provides ongoing advice and 
support to the Authority in its development of national HTA guidelines. The inaugural 
meeting of the SAG was held in June, 2008. The terms of reference for this group 
are to: 
 
 contribute fully to the work, debate and decision-making processes of the Group 
by providing expert technical and scientific guidance at SAG meetings as 
appropriate 
 be prepared to occasionally provide expert advice on relevant issues outside of 
SAG meetings, as requested 
 support the Authority in the generation of Guidelines to establish quality 
standards for the conduct of HTA in Ireland 
 support the Authority in the development of methodologies for effective HTA in 
Ireland 
 advise the Authority on its proposed HTA Guidelines Work Plan and on priorities 
as required 
 support the Authority in achieving its objectives outlined in the HTA Guidelines 
Work Plan 
 review draft guidelines and other HTA documents developed by the Authority and 
recommend amendments as appropriate 
 contribute to the Authority’s development of its approach to HTA by participating 
in an evaluation of the process as required. 
 
In June 2010, following review by the SAG, the draft guidelines were made available 
for broader consultation. Feedback was sought and obtained by open consultation 
through the Authority’s website and by targeted consultation with key stakeholders in 
Irish healthcare.  
 
This document, Guidelines for the Economic Evaluation of Health Technologies in 
Ireland represents the first section of the HTA guidelines. They are limited to the 
methodological guidance on the conduct of economic assessments. They are 
intended to replace the Irish Healthcare Technology Assessment Guidelines, 2000 
and will be reviewed and revised as necessary, with updates provided online through 
the Authority’s website (www.hiqa.ie). 
 
The Authority gratefully acknowledges all those who contributed to the development 
of these guidelines. 
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The membership of the Scientific Advisory Group is as follows: 
 
Chairperson: Dr Michael Barry, 
National Centre for 
Pharmacoeconomics 
Kathy Cargill, Irish Medical & Surgical 
Trade Association (IMSTA) 
Dr Eibhlin Connolly, Department of 
Health and Children 
Dr Davida de la Harpe, Health 
Intelligence, HSE 
John Dowling, Irish Cancer Society 
Representative 
Professor Mike Drummond, Professor 
of Health Economics, University of York 
Shaun Flanagan, Corporate 
Pharmaceutical Unit, HSE 
Dr Gráinne Flannelly, Consultant in 
Obstetrics and Gynaecology** 
Martin Flattery, HIQA 
Dr Patricia Harrington, HIQA 
Dr Loretto Lacey, Janssen 
Immunotherapy^ 
Stephen McMahon, Irish Patients 
Association 
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Epidemiology and Public Health, 
University College Cork* 
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Record of Updates 
 
Date Title / Version Summary of Changes 
2000 Irish Healthcare 
Technology Assessment 
Guidelines 
First national economic guidelines developed 
by the National Centre for 
Pharmacoeconomics in the context defined 
by the agreement between the Irish 
Pharmaceutical Healthcare Association and 
the Department of Health 
November 
2010 
Guidelines for the 
Economic Evaluation of 
Health Technologies in 
Ireland 
Major revision and reorganisation of text 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Guidelines for the Economic Evaluation of Health Technologies in Ireland 
Issued: November 2010 
 
This document is one of a set that describes the methods and processes for 
conducting health technology assessment in Ireland.  
 
The document is available from the HIQA website (www.hiqa.ie).  
 
 
                              Guidelines for the Economic Evaluation of Health Technologies in Ireland 
                                                                           Health Information and Quality Authority 
 10
List of Abbreviations 
 
BIA    budget impact analysis 
CBA    cost-benefit analysis 
CEA    cost-effectiveness analysis 
CEAC    cost-effectiveness acceptability curve 
CPI    Consumer Price Index 
CUA    cost-utility analysis 
EU    European Union 
EUnetHTA   European Network for Health Technology Assessment 
DRG    diagnosis related groups 
HIQA    Health Information and Quality Authority 
HRQOL   health-related quality of life 
HSE    Health Service Executive 
HTA    health technology assessment 
ICER    incremental cost-effectiveness ratio 
LYG    life years gained 
NNT    number needed to treat 
PCRS    Primary Care Reimbursement Service 
PPP    purchasing power parity  
PRSI    Pay Related Social Insurance 
PSA    probabilistic sensitivity analysis 
QALY    quality-adjusted life-year 
RCT    randomised controlled trial 
SAG    Scientific Advisory Group 
TTO    time trade-off 
VAT    Value Added Tax 
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1 Introduction 
 
The health technology assessment (HTA) guidelines provide an overview of the 
principles and methods used in assessing health technologies. They are intended as 
a guide for those involved in the conduct or use of HTAs in Ireland.  
 
The primary audience for HTAs is decision makers within the publicly-funded health 
and social care system. It is recognised that the findings of a HTA may also have 
implications for other key stakeholders in the Irish healthcare system. These include 
patient groups, the general public, clinicians, other healthcare providers, academic 
groups and the manufacturing industry.  
 
The purpose of the HTA guidelines is to promote the production of assessments that 
are timely, reliable, consistent and relevant to the needs of decision makers and key 
stakeholders. 
 
The ‘Economic Guidelines’ represent one component of the planned overall HTA 
guidelines. They are limited to the methodological guidance on the conduct of 
economic assessments. These economic guidelines are intended to replace the Irish 
Healthcare Technology Assessment Guidelines, 2000.(1) The guidelines are of 
relevance to all those conducting economic evaluations and as a reference source for 
those using economic evaluations to inform decision making in the publicly-funded 
health and social care system. They are intended to inform economic evaluations 
conducted by, or on behalf of the Health Information and Quality Authority, the 
National Centre for Pharmacoeconomics, the Department of Health and Children and 
the Health Service Executive (HSE), to include health technology suppliers preparing 
applications for reimbursement.  
 
The guidelines are intended to be applicable to all healthcare interventions, including 
pharmaceuticals, procedures, medical devices, broader public health interventions, 
and service delivery models. They are relevant to the assessment of both new and 
existing technologies. Consequently, the guidelines are broad in scope and some 
aspects may be more relevant to particular interventions than others.  
 
These guidelines have drawn on existing guidelines for economic evaluation and 
published research and will be reviewed and revised as necessary following 
consultation with the various stakeholders, including those in the Scientific Advisory 
Group.  
1.1  Economic guidelines 
The guidelines outline what are considered to be the optimal methods for conducting 
economic assessments in HTA in Ireland. The goal of the guidelines is to inform 
decision making within the publicly-funded health and social care system in Ireland, 
so that the resources available to that system can be used ‘in the most beneficial, 
effective and efficient manner to improve, promote and protect the health and 
welfare of the public’.(2) 
                              Guidelines for the Economic Evaluation of Health Technologies in Ireland 
                                                                           Health Information and Quality Authority 
 12
 
1.1.1  Document layout 
For ease of use, a list of the guideline statements that summarise the key points of 
the guidance is included at the end of this chapter. These guideline statements are 
also included in italics at the beginning of each section for the individual elements of 
the assessment in chapter 2. 
 
1.1.2  Reference case 
Key to any HTA is a high quality, robust economic analysis that is comprehensive, 
transparent and reproducible and includes all relevant evidence on health effects.  
While acknowledging the need for flexibility in reporting studies, a consistent 
methodological approach is required for assessments to facilitate comparisons 
between technologies and disease areas and over time. 
 
These guidelines specify the preferred methods or ‘reference case’ that should be 
used in the primary analysis for HTAs. Use of a standard reference case approach 
increases transparency in the process and confidence that differences in study 
outcomes are representative of differences between technologies as opposed to 
differences in methodologies.  A summary of the reference case is provided in Table 
1.1 on the next page. 
 
The use of a reference case does not preclude the inclusion of other analyses in the 
assessment. However, the rationale supporting the inclusion of additional non-
reference case analyses should be outlined and the information presented separately 
from that of the reference case. It is also recognised that adoption of the reference 
case methods may not always be possible.  
 
The use of any alternate methods in the primary analysis should be clearly 
documented and justified and an attempt should be made to quantify the likely 
consequences of such an approach. 
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Table 1.1 Summary of the reference case 
  
Element of 
Technology 
Assessment 
Reference Case Guideline 
Section 
Evaluation type Cost-utility analysis  2.2 
Perspective on costs The publicly-funded health and social 
care system in Ireland (HSE)* 
2.3 
Perspective on 
outcomes 
All health benefits accruing to 
individuals 
2.3 
Choice of comparator Routine care in Ireland 2.5 
Synthesis of 
effectiveness 
Based on systematic review 2.8 
Outcome measurement QALYS^ 2.11 
Discount rate Apply an annual rate of 4.0% on costs 
and outcomes occurring after the first 
year 
2.13 
Sensitivity analysis Probabilistic and deterministic sensitivity 
analysis 
2.15 
Equity rating No weighting should be applied to the 
outcome measure  
2.16 
* HSE: Health Service Executive 
^ QALYS: quality-adjusted life-years 
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1.2  Summary of Guideline Statements 
 
Study Question (Section 2.1) The study question should be formulated to 
address the needs of the target audience by clearly establishing the context 
of the study. It should outline the purpose of the assessment and provide 
details of the study perspective, the proposed technology and its 
comparator(s), the target population and the impact on specific subgroups, 
where appropriate.  
 
Types of Economic Evaluation (Section 2.2) The preferred evaluation 
type for the reference case is a cost-utility analysis (CUA) with the outcomes 
expressed in terms of quality-adjusted life-years (QALYs). In exceptional 
circumstances, a cost-effectiveness analysis (CEA) with the outcomes 
expressed in terms of life-years gained (or other relevant outcome if the 
technology does not add life-years) may be used as the reference case when 
a cost-utility analysis is an unsuitable choice. Clear, detailed empirical 
evidence must be provided to justify this position. A CEA can be presented as 
a secondary analysis when the use of an important patient outcome (other 
then a QALY) can be justified. 
 
Study Perspective (Section 2.3) For the reference case, the perspective of 
the publicly-funded health and social care system in Ireland should be 
adopted when assessing costs. All health benefits accruing to individuals 
should be included in the assessment of outcomes. 
 
Technology (Section 2.4) The technology should be described in sufficient 
detail to differentiate it from its comparators and to provide context for the 
study. 
 
Choice of Comparator(s) (Section 2.5) The preferred comparator for the 
reference case is ‘routine care,’ that is, the technology or technologies most 
widely used in clinical practice in Ireland. Comparators are not limited to 
specific interventions, but may include alternative treatment sequences or 
alternative rules for starting and stopping therapy. 
 
Target Population (Section 2.6) The target population should be clearly 
defined and the analysis conducted for this entire population using relevant 
efficacy and effectiveness data. Stratified analysis of subgroups (that have 
ideally been identified a priori) is appropriate when there is biological or 
clinical support for heterogeneity in the target population. 
 
Time Horizon (Section 2.7) The time horizon should be of sufficient 
duration to capture any meaningful differences in the future costs and 
outcomes likely to accrue to the competing technologies. The time frame 
adopted should be clearly stated and its choice justified, with the same time 
horizon applied to both costs and outcomes.  
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Efficacy and Effectiveness (Section 2.8) Evidence to support the 
effectiveness of a technology should be derived by systematic review of all 
high-calibre, relevant data. Where available, evidence from randomised 
clinical trials (RCTs) should be used to quantify efficacy in the reference case 
analysis. Meta-analysis may be used to synthesise outcome data provided the 
homogeneity and quality of the studies included justifies this approach. 
 
Safety (Section 2.9) All adverse effects that are of clinical or economic 
importance should be included in the analysis, with particular attention given 
to those that differ substantively between the technologies being compared. 
This evidence should be assembled in a clear, systematic, robust fashion with 
the limitations of the data and methods clearly described. 
 
Measurement of Resource Use and Costs (Section 2.10) Only direct 
costs relevant to the publicly-funded health and social care system should be 
included in the reference case. Resource use in physical units and unit costs 
should be presented in addition to total costs. Costs for the most recent 
calendar year should be used with retrospective input costs inflated using the 
Consumer Price Index for health. Transfer payments (VAT) should be 
excluded. The method used to generate resource use and cost data should be 
systematic, clearly described and justified. 
 
Valuing Outcomes (Section 2.11) For the reference case, health effects 
should be valued in QALYs. Changes in quantity and quality of life should be 
reported separately along with a clear explanation of how the measures were 
combined, the assumptions made and the methods used to estimate QALYs. 
The use of indirect preference-based methods such as the EQ-5D or SF-6D is 
recommended to measure utilities. In the absence of Irish public preference 
data, the population from which preferences are derived should be clearly 
described along with its relevance to the Irish population. 
 
Modelling (Section 2.12) Models used to synthesise and extrapolate 
available evidence should be developed in accordance with good modelling 
practice guidelines. The model should be clearly described, with the 
assumptions and inputs documented and justified. The methods for the 
quality assurance of the model should be detailed and the model validation 
results documented. The model and its key inputs should be subjected to 
comprehensive sensitivity analysis. 
 
Discounting Costs and Benefits (Section 2.13) A standard rate of 4% 
per annum should be used to discount costs and outcomes in the reference 
case. 
 
Heterogeneity (Section 2.14) Stratified analysis of subgroups is 
appropriate to account for differences in cost-effectiveness that may arise due 
to important factors that impact on the target population or its management. 
Subgroups should ideally be identified a priori based on plausible biological, 
clinical or care-setting arguments. 
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Uncertainty (Section 2.15) The effects of model uncertainty (i.e., 
structure, methods and assumptions) and parameter uncertainty on the 
outcome of the economic evaluation must be systematically evaluated using 
sensitivity analysis and scenario analyses for the range of plausible scenarios. 
The range of values provided for each parameter must be clearly stated and 
justified. Justification for the omission of any model input from the sensitivity 
analysis should be included. 
 
For the reference case, a one-way sensitivity analysis should be conducted to 
identify the key model inputs/assumptions contributing most to uncertainty. 
Multivariate analysis should be used for key model inputs. Probabilistic 
sensitivity analysis (PSA), in the form of a Monte Carlo simulation, should be 
used to assess parameter uncertainty. 
 
Equity Considerations (Section 2.16) For the purpose of the reference 
case, additional QALYs gained should be assumed to be of equal value, 
regardless of any considerations for specific characteristics of the population. 
However, an attempt should be made to meet the needs of decision makers 
by highlighting potential equity considerations in the report. 
 
Generalisability (Section 2.17) The overall generalisability of the 
evaluation must be discussed in the context of the validity and relevance of 
the data used in addressing the needs of the target audience. Use of non-
Irish data should be documented and its relevance to the Irish healthcare 
system established. Assumptions should be clearly stated, potential limitations 
identified and variability and uncertainty explored through sensitivity analysis. 
 
Reporting (Section 2.18) A well structured report with information 
provided on each of the elements outlined in the guidelines should be 
provided. Data elements should be tabulated with details provided of their 
source and precision. The distributions used to characterise uncertainty in 
probabilistic analyses should be documented and justified. All results should 
be presented in both their disaggregated and aggregated forms. Expected 
mean costs, total costs and QALYs should be documented for the comparator 
technologies with Incremental Cost-Effectiveness Ratios (ICERs) calculated, 
as appropriate. Uncertainty should be presented graphically (tornado plot for 
one-way sensitivity analysis, scatter plot and cost-effectiveness acceptability 
curves for PSA) and in tabular form to facilitate interpretation. The probability 
that a technology is cost-effective at a range of threshold levels should also 
be presented. 
 
Budget Impact Analysis (Section 2.19) A budget impact analysis should 
be submitted along with the economic evaluation of a technology to best 
inform the needs of the decision maker regarding its affordability and cost-
effectiveness. 
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2 Economic Guidelines in Detail 
 
2.1  Study Question 
The study question should be formulated to address the needs of the target 
audience by clearly establishing the context of the study. It should outline the 
purpose of the assessment and provide details of the study perspective, the 
proposed technology and its comparator(s), the target population and the 
impact on specific subgroups where appropriate. 
 
The primary purpose of HTA is to help inform decision making about the 
value of new and existing technologies. Implicit then is the requirement for 
HTAs to address the needs of decision makers.(3,4) A clear, relevant study 
question should be included that establishes the context of the study. 
 
The study question should outline the purpose of the assessment and detail 
what is included and omitted from the study.  Aspects that should be 
addressed in defining the study question include the: 
 
 study perspective (see also Section 2.3) 
 proposed technology (see also Section 2.4)  
 relevant comparator(s) (see also Section 2.5) 
 target population and the impact of the technology on specific subgroups, 
where appropriate (see also Section 2.6).  
 
Secondary questions that relate to the primary study question should be 
included and clearly specified if they are being addressed as part of the HTA. 
These may include issues such as the reporting of additional outcome 
measures or variations in treatment pathways that are being explored. 
 
2.2  Types of Economic Evaluation 
The preferred evaluation type for the reference case is a cost-utility analysis 
(CUA) with the outcomes expressed in terms of quality-adjusted life-years 
(QALYs). In exceptional circumstances, a cost-effectiveness analysis (CEA) 
with the outcomes expressed in terms of life-years gained (or other relevant 
outcome if the technology does not add life-years) may be used as the 
reference case when a cost-utility analysis is an unsuitable choice. Clear, 
detailed empirical evidence must be provided to justify this position. A CEA 
can be presented as a secondary analysis when the use of an important 
patient outcome (other then a QALY) can be justified. 
 
The aim of health economic evaluations is to compare the costs and 
consequences of new or existing health technologies (e.g. drugs, diagnostics, 
devices, etc.) with one or more relevant alternatives. 
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The type of economic evaluation undertaken is considered to be a factor in its 
value to decision makers. Economic evaluations fall into two major categories:  
 
 cost-effectiveness analysis (including cost-utility analysis as a particular 
sub-type) 
 cost-benefit analysis. 
 
Although they employ similar methods to define and evaluate costs, the 
methods differ in how the consequences are assessed and, therefore, in the 
conclusions drawn. A brief description of these evaluation types including a 
description of cost-minimisation analysis and the particular circumstances for 
its use is included in Appendix 1. 
 
A cost-utility analysis is the preferred evaluation type for the reference case. 
It is considered the gold standard method for conducting economic 
evaluations and is recommended by many expert and consensus groups.(5) 
The preferred outcome measure to be used in the reference case is the 
quality-adjusted-life-year (QALY), (see also Section 2.11.1). The QALY is the 
most widely used outcome measure in cost-utility analysis. It is able to 
simultaneously incorporate changes in the quantity of life and in the quality of 
that life, with the superiority of one technology over another expressed in 
terms of the QALYs gained.(6) The use of a generic measure of outcome such 
as the QALY makes it possible to compare outcomes from different 
technologies across different activities in the healthcare sector.(7) 
 
In a cost-effectiveness analysis (CEA), outcomes are reported in a single unit 
of measurement and are given in natural units(6) (see Appendix 1). For 
programmes whose main effect is to extend life, the usual measure is life 
years gained. The benefit measure may be an intermediate (surrogate) 
marker rather than a final outcome. In exceptional circumstances, a CEA may 
be used as the reference case when a cost-utility analysis is considered an 
unsuitable choice. Clear, detailed, empirical evidence must be provided to 
justify this position that a cost-utility analysis is unsuitable. A CEA may be 
presented as a secondary analysis when the use of an important patient 
outcome (other than the QALY) can be justified. If the benefit measure in the 
CEA is a surrogate or intermediate outcome, there must be a well established, 
validated link between this marker and an important patient outcome.(8) 
Justification should be provided for the extrapolation of changes in surrogate 
markers to clinically relevant effects.  
 
As outlined in Appendix 1, in a cost-benefit analysis (CBA) both costs and 
consequences are presented in monetary terms with the net present value 
determined as the difference in value between costs and benefits.(9) In 
practice, cost-benefit analysis is rarely used in healthcare because of the 
difficulties of expressing health benefits directly in monetary terms.(10,11)  
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In a cost-minimisation analysis (CMA), alternative technologies are compared 
only in terms of their costs because their outcomes (effectiveness and safety) 
are found to be, or are expected to be, identical. The use of a cost-
minimisation analysis may be considered for the reference case if empirical 
justification using robust scientific evidence is provided to support the claim 
that there is no meaningful difference in terms of important patient outcomes 
between the technologies being compared.(12) 
 
2.3  Study Perspective 
For the reference case, the perspective of the publicly-funded health and 
social care system in Ireland should be adopted when assessing costs. All 
health benefits accruing to individuals should be included in the assessment 
of outcomes. 
 
The perspective of a study is the viewpoint from which the study is conducted 
(e.g.  public payer, individual, society) and defines whose costs, resources 
and consequences should be examined. To ensure comparability of analyses, 
this perspective must be clearly stated so that the costs, resources and 
consequences associated with the perspective adopted can be clearly 
identified for inclusion in the economic evaluation. 
 
The costs perspective for the reference case should be that of the publicly-
funded health and social care system, with a view to providing advice that 
maximises health gain for the population and represents the most efficient 
use of the finite resources available to the Health Service Executive (HSE).(12) 
Consistent with this outlook, all health effects accruing to individuals (QALYs, 
life-years gained, etc.) should be included in the outcomes for the reference 
case.  
 
It is recognised that limiting the perspective to that of the primary 
stakeholders in the healthcare system may lead to healthcare policies that fail 
to optimise efficiency and social benefit. Adopting a societal perspective that 
captures all relevant costs and consequences of the technologies in question, 
regardless on whom these costs and consequences fall, is considered the 
most comprehensive approach that can be taken.(4) These may include direct 
and indirect costs, including productivity costs, as well as additional costs, 
savings or other benefits such as non-resource effects (e.g. improved 
education attainment) that may accrue to other public sector agencies, 
patients or their carers as a result of a technology.  
 
If the inclusion of a wider societal perspective is expected to impact on the 
results of the analysis significantly, this may be presented as a secondary 
analysis in addition to the reference case analysis. Non-reference case costs 
should be presented separately, disaggregated from the reference case costs 
in any such additional analyses. These costs should also be subjected to 
sensitivity analysis (see also Section 2.15), and in the instance where 
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quantification is difficult, an estimate of the magnitude of such costs and their 
impact on the results discussed. 
 
2.4  Technology 
The technology should be described in sufficient detail to differentiate it from 
its comparators and to provide context for the study. 
 
In healthcare, technologies include any intervention that may be used to 
promote health, to prevent, diagnose or treat disease, or that is used in 
rehabilitation or long-term care. This includes pharmaceuticals, devices, 
medical equipment, medical and surgical procedures. It also includes the 
organisational and supportive systems within which this healthcare is 
provided. 
 
Adequate information should be provided about the technology under 
assessment. This should include detailed information about its technical 
characteristics (to differentiate it from its comparator technologies), 
regulatory status and the specific application (e.g. purpose, place and 
context) that is being explored as part of the assessment. Pertinent 
information on specific investments, tools required to use the technology, 
additional training and information requirements specific to the technology 
should be included as appropriate. 
 
2.5  Choice of Comparator(s) 
The preferred comparator for the reference case is ‘routine care,’ that is, the 
technology or technologies most widely used in clinical practice in Ireland. 
Comparators are not limited to specific interventions, but may include 
alternative treatment sequences or alternative rules for starting and stopping 
therapy.  
 
To achieve maximum generalisability and transparency, one would need to 
consider all available comparator technologies. The technical difficulty of 
doing this, as well as the additional time and resource implications required 
could make this hugely burdensome and inefficient. In practice, it is 
reasonable to limit the number of comparators to the recommended standard 
of care and those that are used in routine clinical practice in Ireland.  
 
The comparator(s) should be clearly identified and justified with sufficient 
detail provided so that their relevance may be assessed. The choice of 
comparator will critically determine the relative cost-effectiveness of the 
technology and the relevance of the assessment to the decision makers. 
Where the technology and its comparator(s) form part of a treatment 
sequence, a comparison of different sequencing options and the impact of 
variations in the potential sequencing on the cost-effectiveness of various 
options should be considered. 
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For the purpose of the reference case, the comparator should be ‘routine 
care’, that is, the technology or technologies that are most widely used in 
clinical practice in Ireland. It is feasible that there will be more than one 
appropriate comparator technology because of variations in routine practice 
within the Irish healthcare system, including where routine practice differs 
from what is considered best practice (as defined by evidence-based clinical 
practice guidelines) or the most appropriate care.  
 
2.6  Target Population 
The target population should be clearly defined and the analysis conducted 
for this entire population using relevant efficacy and effectiveness data. 
Stratified analysis of subgroups (that have ideally been identified a priori) is 
appropriate when there is biological or clinical support for heterogeneity in 
the target population. 
 
The population for which a technology is being appraised should be clearly 
defined. Parameters to define the population include baseline demographic 
characteristics (e.g. age, gender), disease characteristics (e.g. stage or 
severity, presence of co-morbidities, risk factors), treatment setting (e.g. 
primary care or hospital), or in the context of past treatment (e.g. non-
responders, treatment relapse, non-adherence, poor tolerance). For certain 
technologies, notably medicines, the population will usually be defined by the 
licensed therapeutic indications for the product. 
 
The clinical and cost-effectiveness of a technology should be assessed for the 
entire population specified in the study question. Specific subgroups may be 
identified for whom clinical and cost-effectiveness may be expected to differ 
to that of the overall population. These subgroups should be clearly defined 
and identified based on an a priori expectation of differences in clinical or 
cost-effectiveness and supported by a plausible biological or clinical rationale 
for the subgroup effect. As part of the reference case analysis, differences in 
baseline parameters, treatment costs and effectiveness due to patient 
heterogeneity should be explored by conducting any relevant subgroup 
analyses (see also Section 2.14). 
 
2.7  Time Horizon 
The time horizon should be of sufficient duration to capture any meaningful 
differences in the future costs and outcomes likely to accrue to the competing 
technologies. The timeframe adopted should be clearly stated and its choice 
justified, with the same time horizon being applied to both costs and 
outcomes. 
 
The study period should be clearly described and appropriate to the disease 
and its treatment. This time horizon should be of sufficient length to capture 
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meaningful differences in costs and outcomes between the competing 
technologies. In the interest of consistency, the same time horizon should be 
applied to both costs and outcomes. 
 
A lifetime horizon is usually considered appropriate as the majority of 
technologies have costs and outcomes that impact over a patient’s lifetime. 
This is particularly pertinent for chronic diseases such as diabetes. A shorter 
timeframe may be considered when the costs and outcomes relate to a 
relatively short period of time, such as in an acute infection, and when 
mortality is not expected to differ between the competing technologies. A 
decision to use a shorter timeframe should be justified and an estimate 
provided of any possible bias introduced as a result of this decision. 
 
The use of extrapolation modelling is typically required when adopting a 
lifetime horizon as long-term primary data on the safety and effectiveness of 
a new technology will only be available after the product has been in routine 
clinical use for some time. When extrapolating data beyond the duration of 
the clinical trials, inherent assumptions regarding future treatment effects and 
disease progression should be clearly outlined and tested as part of the 
sensitivity analysis (see also Section 2.15).  
 
2.8  Efficacy and Effectiveness 
For the reference case, evidence to support the effectiveness of a technology 
should be derived by systematic review of all high-calibre, relevant data. 
Where available, evidence from randomised clinical trials (RCTs) should be 
used to quantify efficacy in the reference case analysis. Meta-analysis may be 
used to synthesise outcome data provided the homogeneity and quality of the 
studies included justifies this approach. 
 
The distinction between the efficacy and the effectiveness of a technology is 
recognised. In the context of drugs, efficacy has been defined as ‘clinical 
outcomes derived from patients’ use of a pharmaceutical product in controlled 
settings, typically randomised control Phase I-III trials’.(13) Expanding this 
definition to health technologies in general, the efficacy of a health 
technology relates to its performance under ideal circumstances. In contrast, 
effectiveness refers to the performance of a technology under normal 
circumstances, such as in routine clinical practice.  
 
Outside the arena of marketing authorisation, decision makers are primarily 
concerned with how technologies perform in the context of usual care. 
Economic assessments should be based on the effectiveness of the competing 
technologies and uncertainty surrounding these estimates assessed through 
sensitivity analyses and modelling techniques to enhance the robustness of 
the HTA findings. 
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In the reference case, evidence on outcomes should be obtained by means of 
a systematic review with all data sources clearly described.(14) Evidence 
generated from this phase is necessary to inform decision making, but may 
also be used to populate economic decision-analytic models. These models 
can be used to project the potential health and economic consequences of 
using different technologies over an adequate time frame. 
2.8.1  Locating and Selecting Studies 
In assessing the evidence, the objective is to provide a comprehensive 
reproducible, transparent, unbiased estimate of the outcome parameters for 
the technologies being compared, including an estimate of their relative 
effectiveness. 
 
A clear description of the systematic process used to obtain relevant 
information should be provided.(15) This should include a description of the 
search strategy, inclusion and exclusion criteria applied and restrictions used 
in locating studies (e.g. language, population, year). For best practice, two or 
more reviewers should be involved in the selection process using a pre-
defined protocol to maximise transparency and objectivity. The mechanisms 
used to resolve disagreement should be clearly outlined. A log of the ineligible 
studies should be maintained including a rationale for their individual 
exclusion in relation to the study question. This ensures robustness of the 
search and selection processes. Individual studies selected based on the 
inclusion criteria should be critically assessed for their validity and relevance 
to the study question.(14) 
 
All available evidence should be sought and considered as part of the review 
process. This may also include data that has been identified as commercial or 
academic in confidence. If the validity of a confidence claim is established, a 
clearly defined process should be used to facilitate the use of this data while 
maintaining confidentiality. It should be noted that data confidentiality is 
often for a limited time period. To maximise transparency, data used in the 
formation of HTA decisions should ideally be publicly available, even if it is 
limited to summary data. 
 
To ensure robustness and to minimise publication bias, all attempts should be 
made to include unpublished and partially published studies. These studies 
should be assessed, where possible, using the same validity criteria applied to 
published data.(14) 
 
Whenever available, data from randomised controlled trials (RCTs) should be 
presented in the reference case. A clear rationale for the identification and 
selection of trials should be provided. Inconsistencies between the evidence 
across different data sets and analytical methods should be reported and the 
imprecision or uncertainty regarding the available data explored as part of a 
sensitivity analysis (see Section 2.15). 
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Experimental, quasi-experimental and non-experimental or observational data 
may be submitted to supplement the available RCTs and to enhance the 
generalisability and transferability of the results. This data can be particularly 
valuable when estimating baseline event risks (with existing treatments) and 
for extrapolation of data. The validity of these studies should be assessed as 
part of the critical appraisal. Potential bias arising from the design of these 
studies should be assessed and documented. 
 
Assessment of non-drug technologies including procedures and programmes 
may be more complicated as the evidence-base may be limited and trial 
designs complex. As such, assumptions and uncertainties arising from the use 
of this data should be clearly stated and explored as part of a comprehensive 
sensitivity analysis (see also Section 2.15).  
2.8.2  Summarising the Evidence 
The methods used to analyse or combine data should be clearly outlined and 
justified and the data provided in both aggregated and disaggregated form. 
Meta-analysis may be used to synthesise outcome data, provided there is 
sufficient, relevant and valid data to justify this approach. Particular attention 
should be paid to assessing heterogeneity between studies and testing for 
evidence of publication bias. In the event of limited head-to-head RCT data, 
mixed treatment comparisons can be used. Mixed treatment comparisons 
combine direct and indirect evidence. Inconsistencies between the evidence 
across different data sets and analytical methods should be reported and the 
imprecision or uncertainty regarding the available data explored as part of a 
sensitivity analysis (see Section 2.15). The use of appropriate subgroup 
analyses may be considered where there is known clinical heterogeneity in 
the data (see also Sections 2.6 and 2.14). The homogeneity and quality of the 
primary studies included in the meta-analysis should be discussed when 
developing the overall estimate of the treatment effect, with the justification 
for study inclusion clearly documented. 
 
The treatment effect may be reported in a number of different ways. Both 
absolute (absolute risk reduction, differences in number needed to treat 
[NNT]) and relative effect (odds ratio, risk ratio, relative risk reduction) should 
be presented for binary data. Mean values should be presented for continuous 
variables. The measures of precision of these estimates should also be 
detailed. 
 
If the data limits the use of a quantitative summary, a qualitative summary 
may be provided. The characteristics and limitations of the study data 
included in the analysis should be clearly documented. 
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2.9  Safety 
All adverse effects that are of clinical or economic importance should be 
included in the analysis, with particular attention given to those that differ 
substantively between the technologies being compared. This evidence should 
be assembled in a clear, systematic, robust fashion with the limitations of the 
data and methods clearly described. 
 
Specific definitions have been derived for risks associated with the use of 
pharmaceutical products including definitions for adverse events, serious 
adverse events and adverse drug reactions.(13) International standards are 
also available for manufacturers of medical devices. These specify processes 
to identify the hazards (potential sources of harm) associated with medical 
device use and to estimate and evaluate the risks, to control the risks, and to 
monitor the effectiveness of the controls.(16) The amount and type of safety 
data available for a technology will depend on several factors most notably on 
the timing of the assessment within the lifecycle of the technology. 
 
A structured and systematic approach should be adopted in assessing the 
safety of the product. Rare or infrequent adverse events as well as late-onset 
events are unlikely to be detected as part of RCTs, so the analyst must 
usually rely on case reports, cohort studies, patient registries and 
pharmacovigilance or post-marketing spontaneous reports. The sources of 
information examined should be clearly stated. Standard approaches should 
be taken for the extraction, synthesis and analysis of the evidence and the 
limitations of the data and methods used should be clearly stated when 
interpreting the data.(17) 
 
All adverse events that are of clinical or economic importance should be 
included in the analysis. Particular attention should be paid to those instances 
where there are substantive differences between the technologies being 
compared. In addition to the impact of adverse events on quality of life and 
mortality, consideration should also be given to their impact on patients’ 
ability to comply with therapy (adherence and persistence) as well as possible 
consequences for resource utilisation (e.g. prolongation of hospitalisation, use 
of additional medications, etc.). 
 
2.10  Measurement of Resource Use and Costs 
Only direct costs relevant to the publicly-funded health and social care system 
should be included in the reference case. Resource use in physical units and 
unit costs should be presented in addition to total costs. Costs for the most 
recent calendar year should be used with retrospective input costs inflated 
using the Consumer Price Index for health. Transfer payments (VAT) should 
be excluded. The method used to generate resource use and cost data should 
be systematic, clearly described and justified. 
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Regardless of the perspective adopted in an evaluation, there is a 
requirement for resource use and costs to be identified, measured (in physical 
units) and valued (unit costs applied). These processes must be completed in 
a transparent and consistent manner.(3)  
2.10.1  Resource Identification 
The primary perspective for evaluations should be the publicly-funded health 
and social care system (HSE) in Ireland. Accordingly, for the reference case, 
the resources that should be considered are direct medical costs for the HSE. 
For example, this would include drugs, medical devices, medical services 
including procedures, hospital services and emergency visits, and primary 
care visits. Costs that are borne by patients, but are reimbursable from the 
HSE may also be included in the calculations. Other costs borne by patients 
including productivity costs should be excluded from the reference case. 
These may be included in any secondary analysis that is presented in addition 
to the reference case, where a societal perspective is adopted (see also 
Section 2.3). 
 
Current and future costs arising as a consequence of a technology and that 
occur during the specified timeframe of the study should be included in the 
reference case analysis. Evidence should be presented to demonstrate that 
the data for resource use and costs has been identified systematically. 
 
Cost and resource consumption that are common to all the technologies being 
compared may be excluded from the economic analysis. The process of 
omitting resources should be clearly described and justified.  
 
It is recognised that some technologies have the capacity to impact 
significantly on costs (or savings) to other government departments. While 
these costs should not be included in the reference case, it may be 
appropriate to include them separately in the report. They should be 
accompanied by clear methods of their valuation. 
2.10.2  Resource Measurement 
Resource use data can be obtained from the literature or by primary data 
collection. Sources include RCTs, meta-analysis (synthesising data from 
several sources), clinical practice guidelines, local administration and 
accounting data, and expert opinion. The quality, validity, relevance and 
generalisability of this data to the publicly-funded Irish healthcare setting 
should be clearly described. This data should be subjected to comprehensive 
sensitivity analysis (Section 2.15) to determine the impact of the assumptions 
used in deriving the data. To maximise transparency, consumption of 
resources included in the economic evaluation should be reported in physical 
units of use.  
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2.10.3  Resource Valuation 
Currently, there are no agreed Irish cost models available. As a result, the 
generation of valid Irish cost data is challenging and time consuming. Until a 
valid Irish cost model is established, there is a need for flexibility regarding 
cost valuation. To maximise reproducibility and transferability, all assumptions 
and cost estimates must be clearly reported and subjected to one-way and 
probabilistic sensitivity analysis (see also Section 2.15). To illustrate the 
impact of costs on the results, costs should be varied by +/- 20% in one-way 
sensitivity analyses. In particular, where costs are applied from other 
countries, the assumptions necessary to transfer this data must be explicitly 
reported, with all costs converted to their Irish equivalent in euro using 
Purchasing Power Parity indices.(18) An example of how to transfer costs is 
included in Appendix 2. 
 
There are two general approaches to determining costs: micro-costing and 
gross or macro-costing approaches. The former approach provides a direct 
assessment of unit costs for each input in the treatment of a particular patient 
type. While highly precise, this method is resource intensive and subject to 
bias and issues of generalisability depending on the source of the micro-
costing data. Using aggregated costs such as in the macro-costing approach, 
national average levels for large units of input or output (e.g.  diagnosis-
related group [DRG] or average per diem costs) are applied. While less 
resource intensive and detailed, this data may be more generalisable 
nationally. The use of DRG costs may not always be appropriate (e.g. when 
the definition of the DRG is broad), or where it is unlikely that the mean cost 
reflects resource use in relation to the technology under appraisal. The 
precision of the estimates required and, therefore, the approach to be 
adopted will depend on the importance of each cost category to the 
evaluation. For example, a detailed micro-costing approach for the cost of 
drugs should be used in a comparison of different drug therapies, whereas 
costs for rare or infrequent hospitalisations for adverse effects attributed to 
the drugs may be assigned using a case-mix group cost if available or using a 
per diem rate. 
 
Technology costs in the assessment should therefore reflect their cost to the 
HSE. The source of cost data must be reported with the details of what is 
included in the estimate. Data should be the most recently available, with the 
cost year specified. For the reference case, retrospective input costs should 
be inflated to the most recent calendar year using the Consumer Price Index 
for health.(19) An example of how to inflate retrospective costs is included in 
Appendix 3. If transferring costs from another country, the inflation should be 
calculated using the Consumer Price Index for the local currency prior to 
conversion to the Irish equivalent in euro using Purchasing Power Parity 
indices.(20)  
 
For non-drugs, the public list price should be used in the reference case 
analysis. To reflect the true cost of the technology to the HSE, additional 
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discounts should also be accounted for, but only if these are consistently 
available within the HSE and are known to be guaranteed for the time 
specified. As noted, these costs should be varied as part of a comprehensive 
sensitivity analysis.  
 
For drugs, reimbursement prices may vary depending on the care setting, 
patient eligibility, and the drug formulation prescribed. This may have a 
significant impact on the cost-effectiveness of a technology, whereby it may 
be considered cost-effective through one drug scheme and not through 
another. Pharmacy and wholesale margins and professional dispensing fees 
are set by the Department of Health and Children and vary according to the 
product type, prescription volume and drug scheme through which the drug is 
supplied.(21,22) Care should be taken to include and separately detail the 
prices, margins and fees relevant to the economic evaluation. 
 
In general, the public list price paid for a drug should be used in the 
reference case analysis. Prices for drugs supplied through the community 
drugs schemes are listed in the reimbursement files of the Primary Care 
Reimbursement Service (PCRS) which is updated monthly.(21) For new drugs, 
a system of external reference pricing is used by the government based on a 
currency-adjusted average price to the wholesaler in nine EU Member States. 
In the absence of a published list price, the price submitted by a 
manufacturer for a technology may be used, provided this price would apply 
throughout the HSE. The drug cost used in the reference case should reflect 
that of the product, formulation and pack size that gives the lowest cost, 
provided that this represents a realistic choice for use in clinical practice. Drug 
administration costs, the cost of drug wastage (e.g. from injection vials or 
from patient non-compliance), and the cost of therapeutic drug monitoring 
should be itemised and included where appropriate.  
 
Drug cost estimates should reflect mandatory rebates from pharmaceutical 
manufacturers and importers. These costs may vary with changing 
pharmaceutical policy. A detailed guide for including drug costs in economic 
evaluations is available from the National Centre for Pharmacoeconomics.(23) 
So that the evaluation is relevant to decision making, in certain circumstances 
it may be appropriate to take into account discounted prices in order to reflect 
the true cost to the HSE. The use of price reductions for the HSE should only 
be used if these are consistently available throughout the HSE and are known 
to be guaranteed for the time specified.  
 
Labour (pay) should be calculated using consolidated salary scales available 
from the Department of Health and Children for public-sector employees.(24) 
Associated non-pay costs should be estimated in accordance with the 
methods outlined in the Regulatory Impact Analysis guidelines issued by the 
Department of the Taoiseach,(25) taking into account the most current 
information on the cost of superannuation for the public sector.(26,27) If 
specialist equipment or consumables are also required, these should not be 
included as part of the general non-pay costs, but rather included as 
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separate, specific cost items. An example of how to calculate labour (pay) and 
non-pay costs is included in Appendix 4. 
 
Certain professional fees (such as the dispensing fees and patient care fees 
for pharmacists for drugs dispensed through the community drugs schemes 
and the High Tech Drugs Scheme) are centrally controlled and listed by the 
PCRS.(21)  
 
Value-added tax (VAT) is charged on goods and services provided within the 
state and is controlled by national and European law. VAT rates vary from 0% 
to 21% depending on the classification of the product, with other products 
classified as VAT-exempt. For example, the VAT rate for oral medicines is 0% 
whereas non-oral medicines (including inhalers, topical preparations and 
injectables) attract VAT at a rate of 21%. However, similar to other transfer 
costs, when assessed from the perspective of the government, VAT should be 
excluded from economic evaluations of cost-effectiveness.(20) However, VAT 
at the appropriate rate should be applied to the relevant resources when 
estimating budget impact. 
 
In summary, while published drug cost data exist, the true cost to the HSE is 
impacted by a range of factors that must be considered when preparing the 
assessment. The methods of identifying other cost data are not well defined. 
The origin of the cost data should be clearly identified and justified. Where 
alternative sources are available, the cost chosen should be justified and 
where appropriate, the implications of using alternate data examined by 
sensitivity analysis (see also Section 2.15). 
 
2.11 Valuing Outcomes 
For the reference case, health effects should be valued in QALYs. Changes in 
quantity and quality of life should be reported separately along with a clear 
explanation of how the measures were combined, the assumptions made and 
the methods used to estimate QALYs. The use of indirect preference-based 
methods such as the EQ-5D or SF-6D is recommended to measure utilities. In 
the absence of Irish public preference data, the population from which 
preferences are derived should be clearly described along with its relevance 
to the Irish population. 
 
HTAs provide assessments of both the costs and benefits that accrue as a 
result of the use of alternative technologies. Typically, these benefits include 
a change in patients’ health as a result of the technology. 
2.11.1  Quality-adjusted Life Years 
A quality-adjusted life year (QALY) is a measure of an individual’s length of 
life that has been adjusted for the health-related quality of that life. Gains or 
losses in the quantity of life (mortality) and quality of life (morbidity) are 
therefore combined into a single health outcome measure.(13) 
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QALYs are calculated by assigning a value or weight (utility) to each possible 
health state experienced by the patient. Utilities are measured on an interval 
scale and range in value from 0 (death) to 1 (perfect health). Health states 
considered worse than death are permitted (score of less than zero). 
Summing the product of these values allows a quality adjustment to be made 
to the number of life years gained from a technology so that the relative 
desirability of the health state is reflected in the outcome, e.g.  
 
(Utility A x Years spent in health state A) + (Utility B x Years 
spent in health state B) = X QALYs 
 
Use of the QALY as an outcome measure has two main advantages: it 
incorporates a measure of value or preference for different health states; and 
as a single generic outcome measure, it facilitates comparisons between 
different health programmes as it is universally applicable to all patients and 
diseases. This increases its usefulness to decision makers who are charged 
with the allocation of finite resources between a diverse range of competing 
technologies and as such is recommended for the reference case.  
 
Despite the apparent advantages of the QALY, its valuation may be 
inconsistent as utility weights used in its calculation are instrument-
dependent. The utility measure used to capture health-related quality of life 
should be clearly stated and justified in order to maximise transparency and 
to facilitate comparisons between studies. Changes in the quantity and quality 
of life should be reported separately along with a clear explanation of how the 
measures were combined. Adopting QALYs as the preferred outcome measure 
facilitates comparisons with previous HTAs conducted in Ireland. 
2.11.2 Health-related Quality of Life 
Health-related quality of life (HRQoL) has been defined as ‘a broad theoretical 
construct developed to explain and organise measures concerned with the 
evaluation of health status, attitudes, values and perceived levels of 
satisfaction and general wellbeing with respect to either specific health 
conditions or life as a whole from the individual’s perspective.’(13)  
 
As noted, weighted measures of HRQoL (utilities) are used to calculate 
QALYs. This weighting of HRQoL usually comprises two elements: a 
description of the health state and a valuation of that description.  
 
Utility weights derived by different utility measurement techniques are known 
to give systematically different results.(28) One reason for differences in the 
utility value obtained for similar health states is due to differences in the 
valuation of the health state (e.g. whose preferences are measured and how 
these preferences are captured). The preferences captured can include that 
of the patient or the informed general public. Utilities may be measured 
directly (using standard gamble or time trade-off) or indirectly through a 
generic tool such as the EQ-5D(29) or SF-6D.(30) The indirect tools use data on 
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the HRQoL obtained from patients, but generate a utility score using 
preference values obtained from an ‘informed’ general public.  
 
For the reference case, information on the changes in the health state should 
be reported directly by the patient (or their carer, where relevant). A 
valuation of these changes in the health state should then be obtained using 
preferences elicited from a representative sample of the general population. 
 
A transparent, systematic search (see also Section 2.8.1) should be used to 
gather health utility values from the literature. The choice of data should be 
clearly justified and the methods by which the data was generated clearly 
described. Where several data options are available, the uncertainty arising 
from this should be explored using a sensitivity analysis (see also Section 
2.15). 
 
Use of an indirect preference-based measure, such as the EQ-5D or SF-6D, is 
recommended for the reference case as these measures have widespread 
availability, are easy to use and interpret and because they are based on 
preferences of the general public. The population from which these 
preferences are derived should be clearly described along with their relevance 
to the Irish population. Alternatively, direct HRQoL methods such as time 
trade-off or standard gamble may be used provided these have been 
gathered in a relevant population. 
 
In the absence of relevant utility data from one of these indirect techniques, 
alternative methods may be used including mapping data from other HRQoL 
measures to one of the generic instruments. Mapped utilities should be 
supported by a clear description of the regression model and study on which 
the mapping function is based and should be relevant to the population in 
question. The measure chosen must be fit for purpose, that is, it should 
accurately describe the health states arising in the illness. Details should be 
provided regarding the derivation, validation and relevance of any 
psychometric instrument used along with a description of its supporting 
published evidence. 
 
2.12 Modelling 
Models used to synthesise and extrapolate available evidence should be 
developed in accordance with good modelling practice guidelines. The model 
should be clearly described, with the assumptions and inputs documented and 
justified. The methods for the quality assurance of the model should be 
detailed and the model validation results documented. The model and its key 
inputs should be subjected to comprehensive sensitivity analysis. 
 
The use of extrapolation modelling is typically required as part of an economic 
evaluation to make clinical and cost-effectiveness estimates relevant to the 
time frame under review. It may be necessary to extrapolate short-term 
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outcome data or surrogate measures to long-term outcomes using modelling 
techniques. There are a variety of options to do this including superimposing 
the efficacy estimates from clinical trials on baseline probability estimates of 
survival from population-based sources.(31) Modelling techniques may also be 
used to generalise from clinical trial settings to routine practice, and to 
estimate the relative effectiveness of technologies where these have not been 
directly compared. There is no one optimal modelling technique, rather the 
choice of model should depend on the research question to be addressed. 
Available modelling techniques include decision-tree analysis, state-transition 
or Markov models, and discrete-event simulation. 
 
The model should be transparent with all assumptions explicitly stated. 
Conclusions drawn from the model should be noted to be conditional on these 
assumptions.(3) Good modelling practice should be adhered to, so that the 
quality of the model and the analysis can be ensured.(3,31) To facilitate a 
critical appraisal of the outputs of a model, full documentation of the 
structure, data elements (identification, modelling and incorporation) and 
validation (internal, between-model and external) of the model should be 
addressed in a clear and transparent manner, with explicit justification 
provided for the options chosen. 
2.12.1  Model structure and validity 
The model should be structured so that its inputs and outputs reflect the 
nature of the decision problem and should be sufficiently flexible so that it can 
be readily updated as data become available. 
 
The structure of the model should reflect the true nature of the disease 
process being modelled as closely as possible. In the interest of simplicity, the 
model could be adapted to exclude clinical events not expected to differ 
between the comparator technologies. For state transition models such as 
Markov models, the cycle length should be sufficiently short to ensure that 
multiple changes in disease, treatment decisions or costs do not occur within 
a single cycle. 
 
Limitations in data may constrain choices regarding the model structure. 
Uncertainties in the parameters should be explored through sensitivity 
analysis (see also Section 2.15) and may include the use of alternate model 
structures. Heterogeneity in the modelled population (see also Section 2.14) 
should be accounted for where possible by disaggregating the population into 
biologically or clinically plausible subgroups when there are differences in 
event probabilities, outputs and costs. 
 
The internal validity of the model should be tested thoroughly prior to use to 
ensure that the mathematical logic of the model is robust. The external 
validity of the model can be tested in a number of ways including a 
comparison of the results with those generated by other models and 
explaining differences if they exist. Calibration of the model using 
independent data may also be used, (although in practice such data may be 
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hard to find) again with discrepancies in the findings explained. Counter-
intuitive results generated by the model should be examined and explained. 
The validation, both internal and external, and calibration processes should be 
clearly documented. 
 
Comprehensive sensitivity analyses (see also Section 2.15) of the key model 
parameters should be included using deterministic (one-way or multi-way) 
and probabilistic sensitivity analyses and an attempt made to quantify the 
uncertainty of the results. 
 
2.13 Discounting Costs and Benefits 
A standard rate of 4% per annum should be used to discount costs and 
outcomes in the reference case. 
 
Costs and health outcomes that occur in the future should be discounted to 
present values to reflect society’s rate of time preference.  Accordingly, any 
costs or outcomes occurring beyond one year should be discounted using 
standard methods. 
 
For comparability of results across evaluations, it is important that a common 
discount rate is used. For the reference case, a standard rate of 4.0% per 
annum for costs and outcomes should be used. This is based on guidelines 
from the Department of Finance.(32,32) The discount rate should be varied 
from 0% to 6% in the univariate sensitivity analysis (see also Section 2.15). 
The use of this lower limit allows the impact of discounting to be shown. The 
upper limit incorporates the 5% standard discount rate used in a number of 
other jurisdictions, and thereby facilitates comparisons with other published 
evaluations. 
 
2.14 Heterogeneity  
Stratified analysis of subgroups is appropriate to account for differences in 
cost-effectiveness that may arise due to important factors that impact on the 
target population or its management. Subgroups should ideally be identified a 
priori based on plausible biological, clinical or care-setting arguments. 
 
The cost-effectiveness of a technology may be altered because of differences 
in costs, treatment outcomes or preferences arising from variations by 
treatment setting, by geographical location or because of patient 
heterogeneity (e.g. baseline risk, age, gender). Stratified analyses should be 
used to quantify the differences in cost-effectiveness that may exist in 
different subgroups. These subgroups should ideally be identified a priori with 
their choice clearly justified. The evidence supporting the biological or clinical 
plausibility of the subgroup effect should be fully documented, including 
details of statistical analyses. Since the goal of the health system is to 
maximise the potential for health gain from its finite resources, a stratified 
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analysis that allows cost-effectiveness to be modelled separately for each 
subgroup, may contribute important information to the final advice. 
 
 
2.15 Uncertainty 
The effects of model uncertainty (i.e. structure, methods and assumptions) 
and parameter uncertainty on the outcome of the economic evaluation must 
be systematically evaluated using sensitivity analysis and scenario analyses 
for the range of plausible scenarios. The range of values provided for each 
parameter must be clearly stated and justified. Justification for the omission 
of any model input from the sensitivity analysis should be included. For the 
reference case, a one-way sensitivity analysis should be conducted to identify 
the key model inputs/assumptions contributing most to uncertainty. 
Multivariate analysis should be used for key model inputs. Probabilistic 
sensitivity analysis (PSA), in the form of a Monte Carlo simulation, should be 
used to assess parameter uncertainty.  
 
The primary purpose of sensitivity analysis is to inform the decision maker 
regarding the certainty and robustness of the results and conclusions of the 
economic analysis. It involves the systematic examination of the influence of 
the variables and assumptions used in an evaluation.(33) In a sensitivity 
analysis, critical component(s) in the calculation are varied through a relevant 
range or from worst case to best case, and the results recalculated. These 
ranges and the omission of any model input from the sensitivity analysis 
should be justified.  
2.15.1  Deterministic Sensitivity Analysis  
Deterministic sensitivity analysis examines how parameter variables (included 
as point estimates) impact on model output. These include univariate and 
multivariate sensitivity analysis. 
 
The simplest form of deterministic sensitivity analysis is the univariate or one-
way sensitivity analysis. Here the impact of each variable in the study is 
examined by varying it across a plausible range of values while holding all 
other variables constant at their ‘best estimate’ or baseline value. The 
resulting difference provides some indication of how sensitive the results 
might be to plausible changes in that parameter.(33) Although useful, one-way 
sensitivity analyses do not capture the overall combined uncertainty that may 
be seen when parameters are varied simultaneously.(33)  
 
In a multivariate analysis, two or more parameters are varied simultaneously 
in order to study the combined effect of these parameters on the results of 
the analysis. The greater the number of parameters in the model, the harder 
it becomes to present the results. To overcome this difficulty, the multivariate 
analyses may be presented in the form of scenario analyses, where a series of 
scenarios are constructed that represent a subset of the possible multivariate 
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analyses. Examples include the use of extreme scenarios, corresponding to 
the best-case and worst-case situations, or the use of scenarios the analyst 
views to be probable. If a technology proves to be cost-effective under a 
worst-case scenario, then it is reasonable to predict that it will be cost-
effective if evaluated at the true values of the parameters. 
 
For the reference case, one-way and best/worse case sensitivity analysis are 
an important way of identifying parameters that are key drivers of the model 
and have a substantial impact on the cost-effectiveness. However, they do 
not represent the combined effects of multiple sources of uncertainty. 
 
Sensitivity analysis in the form of threshold analysis may also be used when 
the baseline value of a parameter is unknown. Sensitivity analysis consists of 
estimating threshold values for parameters, above or below which the 
conclusions of the analysis change, e.g. by specifying the maximum 
incremental cost-effectiveness ratio that would be acceptable for a 
technology.  
2.15.2  Probabilistic Sensitivity Analysis 
Probabilistic sensitivity analysis (PSA) is the preferred approach for exploring 
uncertainty arising from parameter imprecision (e.g. uncertainty around the 
true mean values of cost and efficacy inputs) in decision-analytic modelling. 
With this approach, probability distributions are applied using specified 
plausible ranges for the key parameters rather than the use of varied point 
estimates for each parameter. Samples are then drawn at random from these 
distributions through a large number of simulations, as in the Monte Carlo 
simulation method. This enables the uncertainty associated with all 
parameters to be simultaneously reflected in the results of the model. In 
addition to reporting the number of Monte Carlo iterations, the range of 
values for each parameter as well as the distribution range used should be 
reported and justified. The amount that each parameter contributes to 
decision uncertainty should be quantified. Although computationally 
challenging, PSA produces a more realistic assessment of parameter 
uncertainty that the more simplistic deterministic analyses methods.(13) 
 
In economic evaluations it is very important to determine the impact of 
uncertain model inputs and assumptions on the study results.  Potential bias 
and uncertainty may arise from a number of sources in the modelling process. 
These include: 
 
 uncertainty arising out of possible bias in the structure of a model (e.g.  
how health states are categorised or the representation of care 
pathways). Assumptions about the model structure should be clearly 
stated and justified and their impact on cost-effectiveness explored 
though a series of plausible scenario analyses. 
 bias due to selective use of data sources to inform key parameters (e.g.  
estimates of relative efficacy, selection of cost data). These inputs must 
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be fully justified and their impact on the uncertainty of the results 
explored by deterministic sensitivity analysis. 
 uncertainty associated with the precision of the mean parameter values. 
These inputs should be clearly described and justified and their impact on 
cost-effectiveness explored through probabilistic sensitivity analysis. 
 
2.16 Equity Considerations 
For the purpose of the reference case, additional QALYs gained should be 
assumed to be of equal value, regardless of any considerations for specific 
characteristics of the population. However, an attempt should be made to 
meet the needs of decision makers by highlighting potential equity 
considerations in the report. 
  
Achieving equity of health or healthcare is a key consideration of decision 
makers. There are many different ways in which this equity can be 
interpreted. For example, using a basis of equal need there may be a 
requirement for equal expenditure, equal utilisation or equal access to 
healthcare. Alternatively, regardless of need, equity could be defined as equal 
expenditure per capita or a simple criterion that all should enjoy equal health. 
 
The incorporation of equity weights into QALY calculations has been 
proposed, so that societal concerns regarding the severity of health and the 
ability to realise benefits in health are considered. However, there are 
significant methodological issues concerning the derivation of equity weights 
and the circumstances and mechanisms by which these would apply to QALY 
calculations.  
 
Research suggests that among the general public there is preference for 
reducing inequalities in health, particularly those attributed to differences in 
socio-economic status. There is also research to suggest that the public 
attributes a higher social value to improvements in health for those with 
worse lifetime health prospects and to those with dependents, but attributes 
a lower social value to improvements in health for the elderly and more 
controversially, to those perceived to have contributed to their own ill 
health.(34)  
 
The need to address inequalities in healthcare has been used as a criterion for 
prioritising HTA by decision makers. To meet the needs of the decision 
makers, an attempt should be made to include equity considerations in the 
report, such as highlighting unmet needs of certain disadvantaged groups. 
Consideration should also be given to describing the potential impact of a 
technology in addressing this concern.  
 
For the purpose of the reference case, equity weights should not be applied 
to the outcome. Using QALYs as an example, an additional QALY should be 
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assumed to be of equal value regardless of considerations of specific 
characteristics of the population. 
 
 
2.17 Generalisability 
The overall generalisability of the evaluation must be discussed in the context 
of the validity and relevance of the data used in addressing the needs of the 
target audience. Use of non-Irish data should be documented and its 
relevance to the Irish healthcare system established. Assumptions should be 
clearly stated, potential limitations identified and variability and uncertainty 
explored through sensitivity analysis. 
 
Addressing the issues of generalisability and transferability of HTAs has been 
defined as a key principle for the improved conduct of HTA for resource 
allocation decisions. Transferability of economic evaluations across 
jurisdictions has been the subject of an International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) good research 
practices taskforce report. Working definitions employed by the task force 
were that evaluations were generalisable if they could be applied to other 
settings without adjustment. Evaluations were considered transferable if they 
could be adapted to apply to other settings.(35)  
 
These issues are particularly pertinent to the use and transfer of evaluations 
between jurisdictions, e.g.  the use of economic evaluations developed by 
manufacturers or sponsors to support pricing or reimbursement decisions at a 
local or national level.  
 
The European Network of Health Technology Assessment (EUnetHTA) is 
developing a Core Model for HTA that attempts to define and standardise 
elements of HTA. By reducing differences in content across reports, this Core 
Model, which is in development, could facilitate future automated and 
international use of HTA.  A review of the transferability of each assessment 
element and the extent to which transferability of that element is important is 
included in the Core Model.(36) 
 
In the absence of national data, economic evaluation studies often rely on 
international data to develop their recommendations. Specific concerns for 
generalisability of clinical and economic data to HTAs in the Irish healthcare 
setting are: 
 
 the extent to which the clinical efficacy data is representative of the likely 
effectiveness that can be achieved in Ireland  
 the extent to which economic data is representative of the likely costs and 
resource utilisation incurred in Ireland 
 the generalisability of the economic and clinical data across different 
patient populations (e.g. age, gender, ethnicity) within Ireland 
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 the generalisability of data due to local and regional differences in 
healthcare practice within Ireland. 
 
The practice of generalising from efficacy to effectiveness and transferring 
clinical data between countries is usually accepted to be reasonable provided 
the criteria describing the population are clearly described, potential 
differences highlighted and the key parameters subjected to extensive 
sensitivity analysis. While epidemiological data may also be transferable, there 
is greater potential for variability. Any assumptions made should be clearly 
stated, potential limitations identified and variability and uncertainty explored 
through sensitivity analysis. 
 
Economic data is generally not considered to be transferable between 
countries because of differences in the prices or tariffs of the resources used 
and differences in resource consumption due to differing healthcare 
management methods. The absence of an Irish cost database further 
complicates this issue. As outlined in Section 2.10, the quality, validity, 
relevance and generalisability of the cost and resource utilisation data to the 
publicly-funded Irish health and social care setting should be clearly 
described. To maximise transparency, resource use and unit costs should be 
detailed separately to the total costs. Undiscounted, disaggregated cost and 
outcome data should be presented in addition to providing the aggregated, 
discounted summaries.(37) 
 
The overall generalisability of the evaluation must be discussed in the context 
of the validity and relevance of the data used in addressing the needs of the 
target audience. As noted, a primary concern is the extent to which regional 
differences (internal and external) in the costs and effectiveness of a 
technology may contribute to meaningful differences in the cost-effectiveness. 
These differences should be identified and discussed and the likely impact of 
the differences on the results and conclusions of the report highlighted.  
 
2.18 Reporting 
A well structured report with information provided on each of the elements 
outlined in the guidelines should be provided. Data elements should be 
tabulated with details provided of their source and precision. The distributions 
used to characterise uncertainty in probabilistic analyses should be 
documented and justified. All results should be presented in both their 
disaggregated and aggregated form. Expected mean costs, total costs and 
QALYs should be documented for the comparator technologies with ICERs 
calculated, as appropriate. Uncertainty should be presented graphically 
(tornado plot for one-way sensitivity analysis, scatter plot and cost-
effectiveness acceptability curves for PSA) and in tabular form to facilitate 
interpretation. The probability that a technology is cost effective at a range of 
threshold levels should also be presented.  
 
                              Guidelines for the Economic Evaluation of Health Technologies in Ireland 
                                                                           Health Information and Quality Authority 
 39
The economic evaluation report should address the needs of the target 
audience, that is, to provide sufficient information to them to critically 
evaluate the validity of the report and its findings. The report should be well 
structured with information provided on each of the elements outlined in 
these guidelines. Detailed examples to illustrate how results should be 
presented are provided in Appendix 5. 
2.18.1  Presenting Data 
All parameters used in the estimation of clinical and cost-effectiveness should 
be itemised in tabular form with data sources and precision measurements for 
each parameter included. Individual cost components should be presented 
separately as well as being aggregated into total costs. In probabilistic 
sensitivity analysis, the distributions used to characterise the uncertainty 
surrounding each variable should be included.  
2.18.2  Presenting Results 
All results should be reported in detail in both their disaggregated and 
aggregated form. Final results should be tabulated for costs, expected total 
costs and QALYs (or LYG, as appropriate) for each intervention. For QALYs, 
the life-year component should be reported separately. Where appropriate, 
the results for cost-utility analysis should be presented as incremental cost-
effectiveness ratios (ICERs). ICERs present the cost per unit of outcome, e.g.  
the expected additional total cost to the expected additional QALYs (LYG) and 
are calculated as follows: 
 
 
ICER =   (cost A- cost B) 
(outcome of A-outcome of B) 
 
As the ICER becomes larger, the intervention is said to be less cost-
effective.(9) Where more than two technologies are being compared, the 
results should be reported in tabular form, presented in the order of 
increasing costs. Technologies that may be excluded on the basis of simple 
dominance (they are more costly and less effective that the alternatives) are 
eliminated from further calculations. The initial ICER should then be 
calculated by comparing each programme with the one above it, excluding 
those programmes that are dominated. The final ICER is then calculated after 
eliminating technologies that are subject to extended dominance (other 
alternatives available that are more effective and more costly, but provide 
better value for money as identified by the initial ICER).(13) 
 
Uncertainty should also be presented in tabular form for ease of review. In 
addition to the expected mean results (costs, outcomes and ICERs), the 
probability that the intervention is cost-effective at a range of threshold 
values should be reported. For complex cost-effectiveness models fitted using 
simulation methods and where there is considerable uncertainty and 
instability around the estimates of ICERS between alternative technologies, 
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the data should be displayed graphically to facilitate its interpretation. The 
choice of graphics depends on the nature of the analysis, but may include: 
 
 cost-effectiveness plane to present the incremental costs and effects of 
two (or more) comparator technologies 
 tornado diagrams to display the results of subgroup effects and one-way 
sensitivity analysis  
 scatter plots to present ICER results from probabilistic sensitivity analysis 
of two comparator technologies on the cost-effectiveness plane  
 cost-effectiveness acceptability curve to present the probability that a 
technology is more cost-effective than its comparator. In a study 
comparing more that two technologies, it should present the probability 
that a technology is the most cost-effective as a function of the threshold 
willingness to pay for one additional unit of benefit.(13)  
2.18.3  Interpreting Results 
One of the implications of making comparisons regarding the cost-
effectiveness of different technologies, is that a threshold ratio exists above 
which a technology is not considered to be cost-effective. In practice, there is 
no fixed threshold above which an ICER would not be considered cost-
effective, or below which it would. While consideration of the cost-
effectiveness of a technology is necessary, it is not the sole basis for decision 
making.   
 
The principle of what a cost effectiveness threshold represents and how it 
should be used in decisions regarding the allocation of healthcare resources 
has been a source of significant debate in other healthcare settings. These 
may be briefly summarised into three main themes. 
 
Opportunity cost: given a fixed budget, for the publicly funded health 
system, the true opportunity cost of a technology can be assessed in 
terms of what technologies must be foregone or displaced in order to fund 
new, potentially more costly technologies. In the absence of a fixed health 
budget, the true opportunity cost of a new technology must be examined 
in terms of what must be forgone in terms of other publicly-funded sectors 
(e.g. education, housing). In reality, the cost and benefits of all competing 
technologies within the healthcare and other sectors are unlikely to be 
known by the decision makers. It is also of note, that there may be a 
disconnect between the technologies that are displaced in practice to fund 
new technologies, and those that should be displaced based on efficiency 
grounds. The net impact of this may be that the decision to adopt a new 
technology may reduce, rather than increase overall population health.  
 
Willingness-to-pay: the threshold ICER below which a technology would 
always be reimbursed could be informed by research that examines the 
value society attaches to health gain and how this value varies according 
to the population to be treated (equity considerations). In theory, 
however, a tacit value for health gain could be interpreted from the 
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proportion of public expenditure allocated to health relative to other 
competing resources. 
 
Past decisions: the ICER of a new technology could be compared to that 
of other technologies that are currently funded. Such comparisons may be 
helpful when an ICER is substantially lower that that of other technologies 
considered to be cost-effective that were recommended for 
reimbursement, or when an ICER is substantially higher than that of a 
technology previously rejected as not cost-effective. Other factors such as 
equity issues, affordability, resource constraints and the uncertainty 
surrounding the advice have been considered in judging the cost-
effectiveness of a technology for reimbursement.  
 
In summary, there is no fixed cost-effectiveness threshold above or below 
which technologies are guaranteed to be rejected or accepted for 
reimbursement. Several factors may impact on a decision to reimburse a 
technology and any conclusions on cost-effectiveness should be supported by 
the strength of the evidence (e.g. clinical effectiveness, costs, plausibility of 
the inputs and assumptions in the model) and an estimate of the uncertainty 
surrounding the results (e.g. validity of the data, range and plausibility of the 
ICERs, likelihood of error). 
 
2.19 Budget Impact Analysis 
A budget impact analysis should be submitted along with the economic 
evaluation of a technology to best inform the needs of the decision maker 
regarding its affordability and cost-effectiveness. 
 
In addition to assessment of cost-effectiveness, an assessment of the budget 
impact of technologies is increasingly being required by decision makers to 
enable financial planning and to address affordability issues. CEA and budget 
impact analysis (BIA) are viewed as distinct, but complementary approaches 
within a HTA, even though both analyses may share many of the same data. 
The purpose and distinguishing factor of a BIA is that it analyses the net 
financial impact, or affordability, of adopting a new technology relative to the 
current pattern of care. 
 
Detailed guidelines in relation to the conduct of BIA from the perspective of 
the publicly-funded health and social care system in Ireland will be outlined in 
a separate section of the broader HTA guidelines. The purpose of these 
guidelines will be to standardise the method of performing and presenting BIA 
conducted in Ireland, so that decision makers can be provided with 
assessments that are reliable, consistent and relevant to their needs. 
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Appendices 
Appendix 1  
Types of Economic Evaluation 
 
The purpose of this appendix is to provide a brief overview of the different 
types of economic evaluation used in healthcare. A detailed discussion is 
beyond the scope of this document. Instead, readers are referred to the 
reference sources that are available.(9,38)  
 
Economic evaluations fall into two major categories:  
 
 cost-effectiveness analysis  
 cost-benefit analysis. 
 
Although they employ similar methods to define and evaluate costs, the 
methods differ in how the consequences are assessed and, therefore, in the 
conclusions drawn. These evaluation types are briefly described and their 
limitations noted. Also described is cost-minimisation analysis and the 
particular circumstances for its use. 
Cost-effectiveness Analysis  
In a cost-effectiveness analysis (CEA), outcomes are reported in a single unit 
of measurement and are given in natural units.(6) The outcome is common to 
all of the technologies, but may be achieved to various degrees. For 
programmes whose main effect is to extend life, the usual measure is life 
years gained. Sometimes the benefit measure may be an intermediate marker 
rather than a final outcome.(8) Where an intermediate (surrogate) marker is 
chosen it must have a validated, well established link with an important 
patient outcome.(39) The extent to which a clinically relevant effect can be 
precisely predicted based on changes in the surrogate marker should be 
stated. 
 
Limitations 
Cost-effectiveness analysis is limited in that only a single measure can be 
used in the calculation of the cost-effectiveness ratio. It does not reflect the 
effects of a technology on both the quality and quantity of life, nor can it 
reflect the situation where a technology is superior in some measures of 
outcome and inferior in others when compared to another intervention. As the 
measure of primary effectiveness may differ from programme to programme, 
cost-effectiveness analysis cannot be used to make comparisons across a 
broad set of technologies. The concept of cost-utility analysis was developed 
to address these problems.(38) 
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Cost-utility Analysis 
The cost-utility analysis (CUA) enables a broad range of relevant outcomes to 
be included by providing a method through which several outcomes can be 
combined into a single composite summary outcome, such as the QALY.(38) 
This analysis presents the consequences produced by the technologies in 
terms of the life-years gained, with each life-year adjusted by a utility value.  
Utility values are preference-based values that attach to the health state 
produced by a technology. They are measured on a cardinal scale, so that a 
year of life in perfect health has a score of one and death a score of zero.(7) 
There are several methods for obtaining utility values for health states, with 
the choice depending on the study setting and on whose values are 
considered to be the most relevant.(40) Values can be attached to the health 
state using a direct method such as the standard gamble or time trade off 
methods or a rating scale.(9) These values should ideally be attached by 
patients or the general population. The health state valuations should ideally 
be relevant to the population(s) under study(41) since valuation is believed to 
be influenced by culture and income.(42) 
 
The most widely used outcome measure in cost-utility analysis is the quality-
adjusted-life-year (QALY). QALYs combine survival and health-related quality 
of life into a single measurement. By converting the effectiveness data to a 
common unit of measure, such as QALYs gained, a cost-utility analysis is able 
to incorporate simultaneously both the changes in the quantity of life and in 
the quality of life. The superiority of one technology over another can be 
expressed in terms of the QALYs gained. The QALY is useful when changes in 
quality of life are being traded with changes in survival.(6) The use of such a 
generic measure of outcome makes it possible to compare outcomes from 
different technologies across different activities in the healthcare sector.(7) It 
is considered the gold standard method for conducting economic evaluations 
and is recommended by many expert and consensus groups.(5)  
 
Limitations 
There are a number of limitations associated with cost-utility analysis. It has 
been argued that QALYs may suffer from a lack of sensitivity when comparing 
the efficacy of two competing yet similar technologies and in the treatment of 
less severe health problems. Chronic diseases, where quality of life is a major 
issue and survival less of an issue may also be difficult to accommodate in the 
context of the QALY. It has also been argued that preventive measures, 
where the impact on health outcomes may not occur for many years, may be 
difficult to quantify using QALYs.(43) Similarly, there is dispute regarding the 
capacity of QALYs to measure short-term outcomes (e.g. acute pain relief) 
that do not affect the quantity of life and regarding the availability of good 
quality utility values available for certain populations.  
Cost-benefit Analysis  
A cost-benefit analysis (CBA) is the broadest type of analysis; both costs and 
consequences are presented in monetary terms with the net present value 
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determined as the difference in value between the discounted future streams 
of incremental benefits and the incremental costs.(9) This method provides an 
overall view as to whether a technology is economically desirable, i.e., 
whether the benefits of employing a technology outweigh the costs, 
simplifying decisions in the absence of budget constraints. 
 
Money values may be assigned to the health outcomes in a number of ways. 
The value of the consequences may be provided by patients, health 
professionals or by the general population.(9) Two common approaches to the 
conversion of health outcomes to monetary terms are the ‘Willingness to Pay’ 
and the ‘Human Capital’ approach. The former ascertains the maximum 
amount an individual is willing to pay to achieve (or avoid) a particular health 
outcome, or to increase (or decrease) its probability of occurrence. In the 
latter, the value of the healthy time gained from a technology is determined 
by the present value of future earnings.(10) 
 
Limitations 
The use of cost-benefit analysis is limited by the methods used to translate 
benefits to monetary values.(10) In practice, cost-benefit analysis is rarely used 
in healthcare because of the difficulties of expressing health benefits directly 
in monetary terms.(11,44)  
Cost-minimisation Analysis 
In a cost-minimisation analysis (CMA), alternative technologies are compared 
only in terms of their costs because their outcomes (effectiveness and safety) 
are found to be, or are expected to be, identical. Empirical justification using 
robust scientific evidence must be provided to support the claim that there is 
no meaningful difference in terms of important patient outcomes between the 
technologies being compared. 
 
Limitations 
The practical application of cost-minimisation analysis is limited by the 
requirement of equivalent outcomes. With the exception of generic drugs, 
there are a limited number of technologies for which the outcomes are 
expected to be identical. Cost-minimisation analysis may be extended to 
comparisons of drugs with the same mechanism of action that produce 
outcomes that would not be judged to be clinically different (‘me-too’ drugs). 
However, it must be determined that the trial evidence to support equivalence 
was sufficiently powered to detect clinical differences.(12) 
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Appendix 2  
How to Transfer Costs to Ireland using the Purchasing Power Parity 
Index 
 
The OECD details the number of specified monetary units needed in 30 
different countries to buy the same representative basket of consumer goods 
and services. In each case the representative basket costs a hundred units in 
the country whose currency is specified.(45) 
 
The monthly purchasing power parities (PPPs) used to derive the table are 
obtained by extrapolating the 2005 PPPs for private final consumption 
expenditure using the relative rates of inflation between the countries as 
measured by their consumer price indices. Unless a country is a high inflation 
country, its PPP will tend to change slowly over time. Month-to-month 
changes in comparative price levels are more likely to be the result of 
exchange rate fluctuations. Of note: 
 
 for European countries: 
- PPPs for 2006, 2007, 2008 are annual benchmark results 
calculated by Eurostat(46) 
- PPPs for 2009 are OECD estimates 
 for non-European countries, all PPP are OECD estimates based on the 
triennial benchmark results for 2005.  
 
More information is available on the internet site: 
http://www.oecd.org/std/ppp.  
 
Example(18):  
Convert £50 (year 2010) to (Irish costs in €) using the PPP  
 
The representative basket costs a hundred units in the country whose 
currency is specified (U.K. representative costs = 100).  Using the Purchasing 
Power Parities Comparative Price Levels for April 2010,(18), the comparative 
price level is 135 for Ireland.  
 
Representative basket costs 
(U.K.) 100 
Comparative price level for Irish 
basket 135 
2010 value (£) £50 
Converted to Irish costs in € €67.50 
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Appendix 3 
How to Inflate Retrospective Health Costs using the Consumer Price 
Index for Health 
 
Example (19):  
Convert €50 (2006 to 2008) using the CPI for Health  
 
Consumer Price Index by Commodity  
Group, Month and Statistic 
2006 2008 
Period Health Period Health 
2006M01 97.5 2008M01 106.0 
2006M02 98.4 2008M02 107.1 
2006M03 98.4 2008M03 107.2 
2006M04 98.5 2008M04 107.7 
2006M05 99.0 2008M05 108.0 
2006M06 99.1 2008M06 108.0 
2006M07 99.2 2008M07 108.1 
2006M08 99.5 2008M08 109.0 
2006M09 99.5 2008M09 109.1 
2006M10 99.7 2008M10 108.4 
2006M11 100.0 2008M11 109.1 
2006M12 100.0 2008M12 109.0 
Average 99.1 Average 108.1 
 
Using the Formula:  
 
[(Latest Index Number/Earlier Index Number)x100] - 
100 
 
Price increase   =   [(108.1/99.1)x100] – 100 
    
    =   9.08% 
  
Therefore, €50 in 2006 is equivalent to €54.54 in 2008. 
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Appendix 4 
Adjusting for Pay-related Costs in Ireland 
 
Labour (pay) should be calculated using consolidated salary scales available from 
the Department of Health and Children for public-sector employees.(24) An 
average salary cost should be used for the relevant grade by taking a cash value 
mid-way between the lowest and the highest points on the scale.(25)  
 
Associated non-pay costs should be estimated in accordance with the methods 
outlined in the Regulatory Impact Analysis (RIA) guidelines issued by the 
Department of the Taoiseach. This method includes adjustments for non-pay 
costs associated with hiring additional staff including employers’ PRSI, 
superannuation, as well as general overheads such as rent, light and heat, office 
facilities, telephone, general supplies, etc..(25) In 2009, the cost of 
superannuation for healthcare workers in the public sector was identified as 
16.1% of pensionable pay.(26) This figure can be adjusted by adding 2% for 
death-in-service benefit and deducting 5% for the employee contribution to 
generate a net figure of 13.1%.(27)  
 
The total staff cost is calculated as follows: 
 
A Pay Mid-point of pay range 
B Direct Salary Cost A + Employers PRSI 
C Total Salary Cost B + (Imputed Pension Cost = 13.1% of A) 
D Total Staff Cost C + Overheads (40% of A) 
 
Example: 
 
 a staff nurse has 11 points on a pay scale ranging from: €30,234 to 
€43,800 (as of 1st January 2010); the 6th point or mid point of this scale 
is €37,408.  
 direct salary cost is €37,408 + 10.75%(€37,408) = €41,429 
 total salary cost is €41,429 + 13.1%(€37,408) = €46,330 
 total staff cost is €46,330 + 40%(€37,408) =  €61,293 
 therefore, the total cost associated with employing an additional staff 
nurse includes the pay and non pay costs and is estimated at €61,293. 
 
Notes: 
 If specialist equipment or consumables are also required these should not be 
included under the general, non-pay costs, but rather as separate cost items. 
 These are average costs and are applicable only on a general basis. 
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 Formulae for the calculation of daily and hourly rates are available in the RIA 
guidelines and should be consulted, where appropriate. 
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Appendix 5 
Presentation of Results 
 
The results of the base case and sensitivity analysis should be presented in 
tabular and graphical form to aid the understanding of the audience. A number 
of approaches may be used depending on the nature of the analysis. These 
include illustration on the cost-effectiveness plane, tornado diagrams, scatter 
plots and cost-effectiveness acceptability curves. 
 
Comparison of Alternatives - ICERs and their Interpretation  
Where appropriate, the results of the cost-effectiveness analysis (CEA) should be 
presented as incremental cost-effectiveness ratios (ICERs). The ICER describes 
the difference in costs and benefits of the two alternative technologies and 
illustrates the additional benefit achieved for the additional cost incurred. Note, 
one of these alternatives may be ‘no treatment’. 
 
The ICER for technology A compared to technology B is calculated as follows: 
 
ICER  =   (costs of A - costs of B) 
(effects of A - effects of B) 
 
that is, 
=  incremental costs 
incremental effects (benefits) 
 
An ICER therefore presents the incremental cost per additional unit of outcome. 
This could be the cost per case averted, cost per patient treated, cost per LYG or 
cost per QALY gained. The smaller the ICER, the more cost-effective technology 
A is relative to technology B. An ICER that is less than zero may indicate that not 
only is technology A cost-effective compared to technology B, but that it is also 
cost-saving.   
 
Example: HTA of a population-based colorectal screening programme 
in Ireland 
Tables 5.1 shows the lifetime costs and benefits in terms of QALYs for three 
screening scenarios for colorectal cancer compared to a policy of no screening. 
The ‘no screening’ option was the least expensive policy. Once-only flexible 
sigmoidoscopy (FSIG) at age 60 was associated with the smallest increase in 
costs compared to no screening (€3.43 per person). All three screening scenarios 
were associated with small gains in QALYs compared to no screening. The 
maximum health gain was for faecal immunochemical test (FIT)-based screening 
(0.0237 QALYs per person compared to no screening). Combining costs and 
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benefits, and comparing each scenario with no screening, the incremental cost 
per QALY gained was smallest for FSIG (€589), followed by FIT (€1,696) and 
then guaiac-based faecal occult blood test (gFOBT) (€4,428). These ICERs would 
indicate that any of these technologies would be considered highly cost-effective 
compared to a policy of ‘no screening’.   
 
Table 5.1: Incremental cost-effectiveness ratios (ICER), based on 
QALYs, for three screening scenarios for colorectal cancer compared to 
a policy of no-screening 
 
Scenario Cost of 
screening 
and CRC 
management 
per person 
Incremental 
cost per 
person1 
Expected 
QALYs 
per 
person 
Incremental 
QALYs per 
person1 
ICER -
Incremental 
cost per 
QALY 
gained 
No 
screening € 1,074.19 - 10.96 - - 
FSIG 
once at 
60 years 
€ 1,077.62 € 3.43 10.97 0.0058 € 589 
gFOBT at 
55-74 
years 
€ 1,107.82 € 33.63 10.97 0.0076 € 4,4282 
FIT at 
55-74 
years 
€ 1,114.36 € 40.17 10.98 0.0237 € 1,696 
CRC=colorectal cancer; FIT=faecal immunochemical test; FSIG= flexible 
sigmoidoscopy; gFOBT=guaiac-based faecal occult blood test; QALY=quality-adjusted 
life year. Costs and outcomes discounted at 4% 
1 Each incremental value compares value for that strategy to common baseline of no 
screening 
2 gFOBT considered dominated by a combination of FIT and FSIG 
Source: Adapted from Health Information and Quality Authority (2009) Health 
technology assessment (HTA) of a population-based colorectal screening programme in 
Ireland. 
 
 
To aid interpretation, the point-estimates for costs and effects for the alternative 
technologies may be plotted on a cost-effectiveness plane (Figure 5.1). The 
incremental effects are shown on the horizontal axis (i.e., the difference in 
effects between technology A and technology B). The incremental costs are 
shown on the vertical axis (i.e., difference in costs between the two 
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technologies). The cost-effectiveness plane can be considered in four quadrants: 
Q1 to Q4. A point-estimate in Q2 indicates that the new technology, B, is less 
costly and more effective than the alternative, that is, it is said to dominate the 
alternative and would be the preferred option. Conversely, a point estimate in Q4 
would indicate that the new technology is more costly and less effective than its 
alternative, that is, the alterative would be considered the dominant strategy.  A 
point estimate in Q3 indicates that the new technology is less costly, but also 
less effective than the alternative. A decision as to which is the preferred 
strategy would depend on whether the lower cost would make the lower 
effectiveness acceptable. A point estimate in Q1 indicates that the new 
technology is more costly and more effective than the comparator. If a line is 
drawn from the origin to the point-estimate for the new technology, the slope of 
this line represents the ICER. In this scenario, the decision on which technology 
is preferable would depend on how a decision maker is willing to pay for the 
additional benefits associated with the new technology. For the data in table 5.1, 
each of the technologies considered would have a point estimate in Q1 when 
plotted on a cost-effectiveness plane, that is, each technology was estimated to 
be more costly and more effective when compared against a policy of ‘no 
screening’. 
 
Figure 5.1:  Cost-effectiveness Plane 
 
 
Typically, when a series of technologies are being compared, an ICER for each 
technology versus the alternative of usual care is calculated as a first step. The 
technologies may then be compared to one another by computing the ICERs of 
one alternative versus another. This estimates how much additional benefit is 
achieved for the additional cost incurred for each technology compared to the 
other. The information from Table 5.1 is further illustrated on an incremental 
Higher 
effectiveness 
Lower 
effectiveness 
Ceiling Incremental 
Cost-effectiveness ratio 
Higher cost
Lower cost
Q4 Q1 
Q3 Q2
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cost-effectiveness plane in Figure 5.2.  The ICERs for FSIG and FIT can be 
connected with a line of lower slope than a line connecting any other two 
scenarios (indicating a lower cost-effectiveness ratio). A screening intervention 
that has an ICER above the line joining FSIG and FIT, as is the case for gFOBT, 
would be considered dominated (i.e., to be more costly and less effective than 
one, or a combination, of the other strategies). Although less costly than FIT, 
gFOBT is also less effective. It would therefore be considered to be eliminated by 
extended dominance, that is, its costs and benefits are improved by a mixed 
strategy of the two other alternatives FSIG and FIT. 
 
Figure 5.2 Incremental Cost-effectiveness Plane for core screening 
scenarios, based on QALYs  
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ICER (FSIG vs no screening) €589/QALY gained
ICER (FIT vs FSIG)
€2,058/QALY gained
FIT=faecal immunochemical test; FSIG= flexible sigmoidoscopy; gFOBT=guaiac-
based faecal occult blood test; QALY=quality-adjusted life year. Costs and 
outcomes discounted at 4% 
Source: Health Information and Quality Authority (2009) Health technology 
assessment (HTA) of a population-based colorectal screening programme in 
Ireland. 
 
Since FIT was associated with the greatest health gain compared to no 
screening, but FSIG was less costly, the decision to adopt FIT in preference to 
FSIG would depend on the willingness-to-pay of the decision maker. Investing in 
FIT as compared to FSIG would result in an increase in the total costs of €36.74 
(i.e., €40.17 - €3.43) and in the QALYs of 0.0179 (i.e., 0.0237 - 0.0058), yielding 
an ICER of €2,058 per QALY gained. This would be considered highly cost-
effective.   
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Comparison of Alternatives:  Dealing with Uncertainty 
 
Tornado diagram 
A tornado diagram is a useful way to present the results of one-way and multi-
way sensitivity analysis in a single graph. The ICER results are depicted on the 
horizontal axis, while the parameters analysed are depicted on the vertical axis. 
The dotted line represents the results for the Reference case, while the bars 
depict the results for the parameters when tested over the full range of values in 
the sensitivity analysis. Bars that extend beyond €0 indicate where the 
intervention is cost-saving. 
 
Figure 5.3 provides an example of a tornado diagram. The ICER for the 
Reference (base) was less than €2,000 per QALY (€1,696), which would be 
considered highly cost-effective. Most of the parameters considered had 
relatively little impact on the estimates of cost-effectiveness, even when set at 
their most extreme values in the sensitivity analysis. In some instances, the 
intervention became cost-saving compared to no screening (i.e., an ICER less 
than €0 per QALY gained). The most influential parameters were the discount 
rate and costs of colonoscopy. However, even for these most influential 
parameters, the screening scenario remained highly cost-effective in all analyses 
(i.e., an ICER of less than €5,000 per QALY). 
 
Figure 5.3  Tornado diagram of one-way and multi-way sensitivity 
analysis for FIT at 55-74 years 
‐2000 ‐1000 0 1000 2000 3000 4000 5000 6000
FIT uptake
COL compliance
Utility (Ramsey et al)
Proportion who never participate in screening
FIT sensitivity
COL sensitivity
Cost of FIT
Life time costs treating CRC
Cost of COL
Discount rate (costs & QALYs)
Incremental costs € per QALY (ICER)  
Source: Adapted from Health Information and Quality Authority (2009) Health 
Technology Assessment (HTA) of a population-based colorectal screening 
programme in Ireland. 
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Scatter Plot 
For a probabilistic sensitivity analysis (PSA), the analysis is encouraged to 
present the ICER results using the scatter plot on the cost-effectiveness plane, 
as depicted in Figure 5.4. Each symbol on the scatter plot represents one 
simulation of the parameter set. The level of uncertainty in the model is 
characterised by the spread of the point estimates.  
 
Figure 5.4 Cost-effectiveness of the core scenarios: probabilistic 
sensitivity analysis  
*  
Note: Each symbol represents one simulation of the parameter set. 
Source: Health Information and Quality Authority (2009) Health technology 
assessment (HTA) of a population-based colorectal screening programme in 
Ireland.  
 
In Figure 5.4, the spread of both the incremental costs and QALYs was wider for 
the FIT-based screening scenario than for the other options, indicating greater 
uncertainty for this option. Although considerable uncertainty is evident in the 
scatter plot, all three scenarios analysed remained cost-effective in all 
simulations compared to a policy of “no screening”.  In addition, there were 
instances where both FSIG and FIT-based screening appear to be cost-saving 
compared to “no screening”. There is a clear distinction in terms of incremental 
QALYs between FIT screening and screening based on either gFOBT or FSIG, 
with almost all simulations of FIT-based screening associated with greater gains 
in QALYs than the other two options.  In the majority of simulations, the 
incremental costs of screening using gFOBT exceeded those for FSIG, without an 
associated increase in incremental QALYs. 
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Cost-effectiveness Acceptability Curves 
The results of a PSA can be summarised on a single cost-effectiveness plane 
using cost-effectiveness acceptability curves (CEACs). The CEAC for a technology 
gives the probability that a technology is cost-effective across a range of 
willingness-to-pay thresholds. This allows the decision maker to set their own 
threshold ICER for how much they are willing to pay for an additional QALY and 
to see the probability that the technology would be cost-effective at this 
threshold. When a series of technologies are being considered, a cost-
effectiveness acceptability frontier (CEAF) can be plotted. This allows the 
probability that the optimal option (the one with the greatest expected net 
benefit) will be cost-effective at different willingness-to-pay thresholds. 
 
Using the colorectal cancer screening example, Figure 5.5 graphs the CEACs for 
the three screening options compared to a policy of ‘no screening’ and includes 
the cost-effectiveness acceptability frontier (CEAF). If the maximum decision 
makers are willing-to-pay is around €1,000 per additional QALY, the most cost-
effective strategy would be expected to be FSIG once-only at age 60. If the 
willingness-to-pay threshold is increased to between approximately €1,000 and 
€3,000 per additional QALY, biennial FIT in the 55-64 age group would represent 
the screening option most likely to be cost-effective. At a threshold of €4,000 per 
additional QALY or more, the preferred option would be biennial FIT. The CEAF 
shows the probability that the ‘optimal’ option is cost-effective. At a threshold of 
€10,000 or more per additional QALY, there is a greater than 95% probability 
that screening would be cost-effective. 
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Figure 5.5 Example of cost-effectiveness acceptability curves and cost-
effectiveness acceptability frontier for FSIG (once at age 60 years, FIT 
at ages 55-64 and FIT and ages 55-74) 
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Source: Health Information and Quality Authority (2009) Health technology 
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Appendix 6 
 
HTA Glossary 
 
Some of the terms in this glossary will not be found within the body of these 
guidelines. They, they have been included here to make the glossary a more 
complete resource for users. 
Absolute risk: the observed or calculated risk of an event in a defined 
population over a specified time period. (Compare with Relative risk). 
Absolute risk difference or reduction: a type of measure of treatment effect 
that shows the decrease in risk in the treatment group relative to the control 
group, i.e. Pc - Pt. For instance, if the results of a trial were that the probability of 
death in a control group was 25% and the probability of death in a treatment 
group was 10%, then the absolute risk reduction would be 25% - 10% = 15%. 
It is the inverse of the number needed to treat. (See also Number needed to 
treat and Odds ratio and Relative risk reduction.) 
Accuracy: the extent to which a measurement, or an estimate based on 
measurements, represents the true value of the variable being measured. (See 
also Validity). 
Adverse event: an undesirable effect of a health technology. 
Attributable risk or attributable fraction: with a specified outcome, 
exposure factor, time period and population, the rate of an outcome that can be 
attributed to the factor in the population (i.e. net of background risk). The 
population should be specified as either the exposed or total population. 
Base case: see Reference case. 
Base case analysis: the results of the economic evaluation estimating how 
much it would cost to achieve additional health outcomes with the proposed 
technology compared with the main comparator, presented as an incremental 
cost-effectiveness ratio, and incorporating the costs associated with altered uses 
of drugs, medical and other related healthcare resources and all outcomes 
valued in terms of overall quality and length of life. (See also Reference case 
analysis). 
Baseline: a term used to describe the initial set of measurements taken at the 
beginning of a study (after a run-in period, when applicable). 
Baseline risk: at the time when a participant is enrolled in a study or when a 
patient is treated with a technology, baseline risk is the risk of future events of 
interest in the absence of that technology. 
Bayesian Method: a branch of statistics that uses prior information on beliefs 
for estimation and inference. 
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Bias: systematic (as opposed to random) deviation of the results of a study from 
the “true” results. 
Blinding: when study participants, caregivers, researchers and outcome 
assessors are kept unaware about the technologies that the people have been 
allocated to in a study. 
Budget impact analysis (BIA) or financial analysis: a procedure for 
comparing only the financial costs and cost offsets of competing options, rather 
than comparing their clinical and economic costs and benefits.  
Capital costs: the costs of buying land, buildings or equipment (e.g.  medical 
equipment) to provide a service (e.g.  healthcare). 
Case-control study: a retrospective observational study designed to determine 
the relationship between a particular outcome of interest (e.g.  disease or 
condition) and a potential cause (e.g.  a technology, risk factor, or exposure). 
For example, a group of people with lung cancer might be matched with a group 
of people the same age without lung cancer.  The researcher could compare how 
often both groups had been exposed to tobacco smoke in their lives. 
Cohort study: an observational study in which two or more sub-sets of defined 
populations are identified by the presence of a common factor or factors (e.g.  
non-randomly assigned to the proposed technology or to its main comparator(s)) 
and then followed in time to investigate the influence of the factors on the 
probability of occurrence of an outcome or outcomes. 
Common reference: a drug or technology to which a proposed technology and 
its main comparator(s) have been compared in separate comparative randomised 
trials. 
Comorbidity: the coexistence of a disease, or more than one disease, in a 
person in addition to the disease being studied or treated. 
Composite outcome: a pre-specified outcome of a trial, which is recorded as 
occurring for a trial participant when any one of several component outcomes of 
the composite is experienced. 
Comparator: the alternative against which the intervention is compared. 
Confidence interval: the computed interval with a specified probability (by 
convention, 95%) that the true value of a variable such as mean, proportion, or 
rate is contained within the interval. 
Confounding: the distortion of a measure of the effect of an exposure (e.g. to 
therapy involving the proposed drug) on the risk of an outcome under 
investigation brought about by the association of the exposure with other 
factor(s) that can influence the outcome. 
Consumer Price Index: this index measures the change in the average price 
levels (including all indirect taxes) paid for consumer goods and services by all 
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private households in the country and by foreign tourists holidaying in the 
country. 
Control group: a group of participants who are observed but who do not 
receive treatment involving the proposed drug or technology. They may receive 
alternative treatment, no treatment or placebo. They provide data on the 
streams of outcomes (clinical and economic) for comparison with the streams of 
outcomes observed for participants who take therapy involving the proposed 
drug or technology. 
Cost: the value of opportunity forgone, as a result of engaging resources in an 
activity (see opportunity cost); there can be a cost without the exchange of 
money; range of costs (and benefits) included in a particular economic 
evaluation depends on perspective taken; average costs are average cost per 
unit of output (i.e., total costs divided by total number of units produced); 
incremental costs are extra costs associated with intervention compared to 
alternative; marginal cost is cost of producing one extra unit of output. 
Cost, financial: the monetary value of providing a resource accounted for in 
the budget of the provider. 
Cost analysis: a partial economic evaluation that only compares the costs in 
monetary units of the proposed technology with its main comparator(s). 
Cost-benefit analysis (CBA): an economic evaluation that compares the 
proposed technology with its main comparator(s) in which both costs and 
benefits are measured in monetary terms to compute a net monetary gain/loss 
or benefit gain/loss. 
Cost-consequences analysis (CCA): an economic evaluation that compares 
the proposed technology with its main comparator(s) as an array of all material 
costs and outcomes measured in their natural units rather than a single 
representative outcome as presented in a cost-effectiveness analysis. 
Cost-effective (value for money): a proposed technology is considered cost-
effective for a specified main indication if the incremental benefits of the 
proposed technology versus its main comparator(s) justify its incremental costs 
and harms. 
Cost-effectiveness acceptability curves (CEAC): a graph plotting a range of 
possible cost-effectiveness thresholds on the horizontal axis against the 
probability that the intervention will be cost-effective on the vertical access. 
CEAC provide a visual representation of the uncertainty surrounding cost-
effectiveness estimates. 
Cost-effectiveness analysis (CEA): an economic evaluation that compares, 
for example, a proposed technology with its main comparator(s) having common 
clinical outcome(s) in which costs are measured in monetary terms and 
outcomes are measured in natural units, e.g.  reduced mortality or morbidity. 
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Cost-effectiveness frontier: a region on a plot that shows the probability that 
the technology with the highest expected net benefit is cost effective. 
Cost-effectiveness plane: a graph plotting difference in effect (between the 
technology of interest and the comparator) on the horizontal axis against the 
difference in costs on the vertical access, providing a visual representation of 
cost-effectiveness.  
Cost-minimisation analysis (CMA): an economic evaluation that finds the 
least costly alternative technology, for example, after the proposed technology 
has been demonstrated to be no worse than its main comparator(s) in terms of 
effectiveness and adverse events. 
Cost-utility analysis (CUA): an economic evaluation that compares the 
proposed technology with its main comparator(s) in which costs are measured in 
monetary terms and outcomes are measured in terms of extension of life and the 
utility value of that extension, e.g. using quality-adjusted life years (QALYs). 
Critical appraisal: a strict process to assess the validity, results and relevance 
of evidence. 
Data synthesis: combining evidence from different sources. 
Decision analysis: a technique that formally identifies the options in a decision 
making process, quantifies the probable outcomes (and costs) of each, 
determines the option that best meets the objectives of the decision maker and 
assesses the robustness of this conclusion.  
Decision tree: a graphical representation of the probable outcomes following 
the various decision options in a decision analysis. 
Deterministic sensitivity analysis (DSA): a method of decision analysis that 
uses both one-way (variation of one variable at a time) and multi-way (two or 
more parameters varied at the same time) sensitivity analysis to capture the 
level of uncertainty in the results that may arise due to missing data, imprecise 
estimates or methodological issues. (Compare: Probabilistic sensitivity 
analysis.) 
Dichotomous data: data that are classified into either one of two mutually 
exclusive values, for example, ‘yes’ and ‘no’ or ‘cured’ and ‘not cured.’ 
Direct costs: the fixed and variable costs of all resources (goods, services, etc.) 
consumed in the provision of a technology as well as any consequences of the 
intervention such as adverse effects or goods or services induced by the 
intervention. These include direct medical costs and direct non-medical costs 
such as transportation or child care. 
Direct medical costs: Medical costs that vary with the healthcare provided 
(e.g.  doctors’ salaries). 
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Direct non-medical costs: the non-medical costs of treating a patient, e.g.  
transportation provided to and from a medical appointment. 
Disability-adjusted life years (DALYs): a unit of healthcare status that 
adjusts age-specific life expectancy by the loss of health and years of life due to 
disability from disease or injury. DALYs are often used to measure the global 
burden of disease. 
Discounting: the process used in economic analyses to convert future costs or 
benefits to present values using a discount rate. Discounting costs reflects 
societal preference for costs to be experienced in the future rather than the 
present. Discounting benefits reflects a preference for benefits to be realised in 
the present rather than at a later date.  
Discount rate: the interest rate used to discount or adjust future costs and 
benefits so as to arrive at their present values, e.g.  4%. This is also known as 
the opportunity cost of capital investment.  
Discrete-event simulation (DES): a collection of techniques for modelling 
one or more phenomena of interest in a system that change value or state at 
discrete points in time. DES allows all characteristics of the system to be 
represented. Unlike Markov models, the primary focus in DES is on the 
occurrence of events rather than transitions or states. (See also Markov 
Model.) 
Dominance (simple, strong or strict): a technology is dominated if it has 
higher costs and worse outcomes than an alternative technology. 
Economic evaluation: application of analytical methods to identify, measure, 
value, and compare costs and consequences of alternatives being considered; 
addresses issue of efficiency to aid decision making for resource allocation. It is 
an umbrella term covering CBA, CEA, CMA and CUA.  
Economic model: economic models provide a means of bringing together 
different types of data from a range of sources and provide a framework for 
decision making under conditions of uncertainty.  Modelling may be used to 
combine different data sets changing the information collected from a clinical 
trial into a form that can be used, to extrapolate short-term clinical data to 
longer term, to link intermediate with final endpoints, to generalise from clinical 
trial settings to routine practice and to estimate the relative effectiveness of 
technologies where these have not been directly compared in clinical trials.   
Effectiveness: the extent to which a technology produces an overall health 
benefit (taking into account adverse and beneficial effects) in routine clinical 
practice. (Contrast with Efficacy.) 
Efficacy: the extent to which a technology produces an overall health benefit 
(taking into account adverse and beneficial effects) when studied under 
controlled research conditions. (Contrast with Effectiveness.) 
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Epidemiology: the study of the distribution and determinants of health-related 
conditions or events in defined populations. 
Equity: as it relates to health, ‘fairness’ in allocation of resources, technologies, 
or outcomes among individuals or groups. 
EQ-5D: the EQ-5D is a standardised instrument (questionnaire) used to measure 
health outcomes. The instrument is applicable to a wide range of health 
conditions and treatments and can be used to generate a single index value for 
health status. The EQ-5D questionnaire describes five attributes (mobility, self-
care, usual activity, pain/discomfort, and anxiety/depression) each of which has 
three levels (no problems, some problems, and major problems). This 
combination defines 243 possible health states which added to the health states 
‘unconscious’ and ‘dead’, allow for 245 possible health states. Each EQ-5D health 
state (or profile) provides a set of observations about a person by way of a five-
digit code number. This EQ-5D health state is then converted to a single 
summary index by applying a formula that attaches weights to each of these 
levels in each dimension and subtracting these values from 1.0. Additional 
weights that are applied are a constant (for any deviation from perfect health) 
and a weight if any of the dimensions are at level three (major problems). The 
scores fall on a value scale that ranges from 0.0 (dead) to 1.0 (perfect health). 
For further information on EQ-5D see: www.euroqol.org. 
Evidence-based medicine: the use of current best evidence from scientific 
and medical research to make decisions about the care of individual patients. It 
involves formulating questions relevant to the care of particular patients, 
searching the scientific and medical literature, identifying and evaluating relevant 
research results, and applying the findings to patients.   
Extrapolation: the prediction of parameter values outside the range of 
observed values in an analysis. 
Extended (or weak) dominance: state when intervention is more costly and 
more effective, and has lower incremental cost-effectiveness ratio, than 
alternative. 
External validity: the extent to which one can generalise study conclusions to 
populations and settings of interest outside study. 
Extrapolation: prediction of value of model parameter outside measured range 
or inference of value of parameter of related outcome (e.g.  extrapolation of 
reduction in rate of progression to AIDS from improvement in HIV viral load). 
Final outcome: a health outcome that is directly related to the length of life, 
e.g. life-years gained or quality-adjusted life years. 
Follow-up: the observation over a period of time of study/trial participants to 
measure changes in outcomes under investigation. 
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Generalisability: the problem of whether one can apply or extrapolate results 
obtained in one setting or population to another; term may also be referred to as 
‘transferability’, ‘transportability’, ‘external validity’, ‘relevance’, or ‘applicability’. 
Grey literature: research reports that are not found in traditional peer-
reviewed publications, e.g.  government agency monographs, symposium 
proceedings, and unpublished company reports. 
Gross or macro costing: costing approach that uses large components as 
basis for costing, such as cost per hospital day; compare with Micro-costing.  
Hazard ratio: a measure of effect produced by a time-to-event survival 
analysis. This represents the increased instantaneous rate with which one group 
is likely to experience the outcome of interest. 
Health outcome: a change (or lack of change) in health status caused by a 
therapy or factor when compared with a previously documented health status 
using disease-specific measures, general quality of life measures or utility 
measures. 
Health-related quality of life (HRQoL): a combination of the physical, social 
and emotional aspects of an individual’s life that are important for their well-
being. 
Health technology: the application of scientific or other organised knowledge – 
including any tool, technique, product, process, method, organisation or system 
– in healthcare and prevention.  In healthcare, technology includes drugs, 
diagnostics, indicators and reagents, devices, equipment, and supplies, medical 
and surgical procedures, support systems and organisational and managerial 
systems used in prevention, screening diagnosis, treatment and rehabilitation. 
Health technology assessment (HTA): this is a multidisciplinary process that 
summarises information about the medical, social, economic and ethical issues 
related to the use of a health technology in a systematic, transparent, unbiased, 
robust manner.  Its aim is to inform the formulation of safe, effective health 
policies that are patient-focused and seek to achieve best value. 
Heterogeneity: in the context of meta-analysis, clinical heterogeneity means 
dissimilarity between studies. It can be because of the use of different statistical 
methods (statistical heterogeneity), or evaluation of people with different 
characteristics, treatments or outcomes (clinical heterogeneity). Heterogeneity 
may render pooling of data in meta-analysis unreliable or inappropriate. Finding 
no significant evidence of heterogeneity is not the same as finding evidence of 
no heterogeneity. If there are a small number of studies, heterogeneity may 
affect results but not be statistically significant. 
Homogeneity: used to describe when the results of studies included in a 
systematic review or meta-analysis are similar and there is no more variation 
than would occur by chance alone. Results are usually regarded as homogenous 
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when any difference observed between studies could reasonably be expected to 
occur by chance alone. 
Incremental costs: the absolute difference between the costs of alternative 
management strategies of the same medical condition, disease or disorder. 
Incremental cost-effectiveness ratio (ICER): the results of a cost-
effectiveness analysis (CEA) are presented as an incremental cost-effectiveness 
ratio (ICER) and this describes how much additional benefit is achieved for the 
additional cost incurred.  The ICER for two technologies A and B is calculated as 
follows:   
ICER = (cost of A – cost of B)/ (effects of A – 
effects of B) 
Indication: a clinical symptom or circumstance indicating that the use of a 
particular intervention would be appropriate. 
Indirect costs: the cost of time lost from work and decreased productivity due 
to disease, disability, or death. (In cost accounting, it refers to the overhead or 
fixed costs of producing goods or services.) 
Indirect preference measurement: use of instruments (e.g.  Health Utilities 
Index and EQ- 5D) to measure preferences, without undertaking direct 
measurement. 
Intangible costs: the cost of pain and suffering resulting from a disease, 
condition, or intervention. 
Intention-to-treat analysis: a type of analysis of clinical trial data in which all 
patients are included in the analysis based on their original assignment to 
intervention or control groups, regardless of whether patients failed to fully 
participate in the trial for any reason, including whether they actually received 
their allocated treatment, dropped out of the trial, or crossed over to another 
group. 
Internal validity: a trial has internal validity if, apart from possible sampling 
error, the measured difference in outcomes can be attributed only to the 
different therapies assigned.  
Literature review: a summary and interpretation of research findings reported 
in the literature. This may include unstructured qualitative reviews by single 
authors as well as various systematic and quantitative procedures such as meta-
analysis.  
Marginal benefit: the additional benefit (e.g.  in units of health outcome) 
produced by an additional resource use (e.g.  another healthcare intervention). 
Marginal cost: the additional cost required to produce one additional unit of 
benefit (e.g. unit of health outcome).   
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Markov Model: a type of quantitative modelling that involves a specified set of 
mutually exclusive and exhaustive states (e.g.  of a given health status), and for 
which there are transition probabilities of moving from one state to another 
(including of remaining in the same state). Typically, states have a uniform time 
period, and transition probabilities remain constant over time. 
Meta-analysis: systematic methods that use statistical techniques for 
combining results from different studies to obtain a quantitative estimate of the 
overall effect of a particular intervention or variable on a defined outcome. This 
combination may produce a stronger conclusion than can be provided by any 
individual study. (Also known as data synthesis or quantitative overview). 
Micro-costing: costing approach based on detailed resources used by patient 
on item by item basis; compare with gross costing. 
Monte Carlo simulation: a technique used in computer simulations that uses 
sampling from a random number sequence to simulate characteristics or events 
or outcomes with multiple possible values. For example, this can be used to 
represent or model many individual patients in a population with ranges of 
values for certain health characteristics or outcomes. In some cases, the random 
components are added to the values of a known input variable for the purpose of 
determining the effects of fluctuations of this variable on the values of the output 
variable. 
Net benefit: refers to a method of reporting results of economic evaluations in 
terms of monetary units (called net monetary benefit) or units of outcome (called 
net health benefit); in cost-benefit analysis, (incremental) net benefit is the 
difference in total benefit and total cost of the technology less the difference in 
total benefit and total cost of the comparator. 
Non-randomised controlled trial (Non-RCT): a controlled clinical trial that 
assigns patients to intervention and control groups using a method that does not 
involve randomisation, e.g.  at the convenience of the investigators or some 
other technique such as alternate assignment. 
Number needed to treat (NNT): a measure of treatment effect that provides 
the number of patients who need to be treated to prevent one outcome event. It 
is the inverse of absolute risk reduction (1 ÷ absolute risk reduction); i.e., 1.0 ÷ 
(Pc - Pt). For instance, if the results of a trial were that the probability of death in 
a control group was 25% and the probability of death in a treatment group was 
10%, the number needed to treat would be 1.0 ÷ (0.25 - 0.10) = 6.7 patients. 
(See also Absolute risk reduction, Relative risk reduction, and Odds 
ratio.) 
Observational study: a study in which the investigators do not manipulate the 
use of, or deliver, a technology (e.g.  do not assign patients to treatment and 
control groups), but only observe patients who are (and sometimes patients who 
are not as a basis of comparison) exposed to the intervention, and interpret the 
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outcomes. These studies are more subject to selection bias than experimental 
studies such as randomised controlled trials. 
Odds ratio: a measure of treatment effect that compares the probability of a 
type of outcome in the treatment group with the outcome of a control group, 
i.e., [Pt ÷ (1 - Pt)] [Pc ÷ (1 - Pc)]. For instance, if the results of a trial were that 
the probability of death in a control group was 25% and the probability of death 
in a treatment group was 10%, the odds ratio of survival would be [0.10 ÷ (1.0 - 
0.10)] ÷ [(0.25 ÷(1.0 - 0.25)] = 0.33. (See also Absolute risk reduction, 
Number needed to treat, and Relative risk.) 
Opportunity cost: costs of resources consumed expressed as value of next 
best alternative for using resources. 
Outcome: consequence of condition or intervention; in Economic Guidelines, 
outcomes most often refer to health outcomes, such as surrogate outcomes or 
patient outcomes. 
Peer review: the process by which manuscripts submitted to health, 
biomedical, and other scientifically oriented journals and other publications are 
evaluated by experts in appropriate fields (usually anonymous to the authors) to 
determine if the manuscripts are of adequate quality for publication. 
Perspective: this is the viewpoint from which an economic evaluation is 
conducted. Viewpoints that may be adopted include that of the patient, the 
public healthcare payer or society. 
Purchasing power parity: this theory states that in an efficient market, the 
exchange rate of two currencies results in equal purchasing power. The 
purchasing power indices are currency conversion rates that both convert to a 
common currency and equalise the purchasing power of different currencies. In 
other words, they eliminate the differences in price levels between countries in 
the process of conversion.  
Prevalence: the number of people in a population with a specific disease or 
condition at a given time and is usually expressed as a ratio of the number of 
affected people to the total population. 
Primary study: an investigation that collects original (primary) data from 
patients, e.g.  randomised controlled trials, observational studies, series of cases, 
etc.. 
Probability: expression of degree of certainty that event will occur, on scale 
from zero (certainty that event will not occur) to one (certainty that event will 
occur). 
Probability distribution: portrays the relative likelihood that a range of values 
is the true value of a treatment effect. This distribution often appears in the form 
of a bell-shaped curve. An estimate of the most likely true value of the treatment 
effect is the value at the highest point of the distribution. The area under the 
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curve between any two points along the range gives the probability that the true 
value of the treatment effect lies between those two points. Thus, a probability 
distribution can be used to determine an interval that has a designated 
probability (e.g.  95%) of including the true value of the treatment effect. 
Probabilistic sensitivity analysis (PSA): a type of sensitivity analysis where 
probability distributions are applied to a plausible range of values for key 
parameters to capture uncertainty in the results. A Monte Carlo simulation is 
performed and a probability distribution of expected outcomes and costs is 
generated. (Contrast with Deterministic sensitivity analysis). 
Productivity costs: the costs associated with lost or impaired ability to work 
because of morbidity or death. 
Prospective study: a study in which the investigators plan and manage the 
intervention of interest in selected groups of patients. As such, investigators do 
not know what the outcomes will be when they undertake the study. (Contrast 
with Retrospective study.) 
Publication bias: unrepresentative publication of research reports that is not 
due to the quality of the research but to other characteristics, e.g.  tendencies of 
investigators to submit, and publishers to accept, positive research reports (i.e., 
ones with results showing a beneficial treatment effect of a new intervention). 
Quality-adjusted life year (QALY): a unit of healthcare outcomes that 
adjusts gains (or losses) in years of life subsequent to a healthcare intervention 
by the quality of life during those years. QALYs can provide a common unit for 
comparing cost-utility across different technologies and health problems. 
Analogous units include disability-adjusted life years (DALYs) and healthy-years 
equivalents (HYEs). 
Randomised controlled trial (RCT): a trial in which participants are randomly 
assigned to one or more treatment groups and a control group.  
Reference case or base case: this specifies the methodologies considered 
most appropriate to be used in the assessment of clinical and cost-effectiveness 
when conducting HTA on, or behalf of the Health Information and Quality 
Authority.  
Relative risk difference or reduction: a type of measure of treatment effect 
that compares the probability of a type of outcome in the treatment group with 
that of a control group, i.e.: (Pc - Pt) ÷ Pc. For instance, if the results of a trial 
show that the probability of death in a control group was 25% and the 
probability of death in a treatment group was 10%, the relative risk reduction 
would be: (0.25 - 0.10) ÷ 0.25 = 0.6. (See also Absolute risk reduction, 
Number needed to treat, and Odds ratio.) 
Sample size: the number of patients studied in a trial, including the treatment 
and control groups, where applicable. In general, a larger sample size decreases 
the probability of making a false-positive error (α) and increases the power of a 
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trial, i.e., decreases the probability of making a false-negative error (β). Large 
sample sizes decrease the effect of random variation on the estimate of a 
treatment effect. 
Sensitivity analysis: a means to determine the robustness of a mathematical 
model or analysis by examining the extent to which results are affected by 
changes in methods, parameters or assumptions.   
SF-36: the SF-36 is a standardised instrument (questionnaire) used to measure 
health outcomes. It is a multi-purpose, short-form health survey with 36 
questions. It yields an 8-scale profile of functional health and well-being scores 
as well as psychometrically-based physical and mental health summary measures 
and a preference-based health utility index. It is a generic measure, as opposed 
to one that targets a specific age, disease, or treatment group. Accordingly, the 
SF-36 has proven useful in surveys of general and specific populations, 
comparing the relative burden of diseases, and in differentiating the health 
benefits produced by a wide range of different treatments.  
For further information on SF-36 see: www.sf-36.org. 
Standard gamble: a method of preference assessment used to measure 
utilities, that is, to ascertain an individual’s preference for different health states 
that differ in quantity or quality of life. Preference is ascertained be choosing 
between a given health state, or gambling between perfect health and 
immediate death. The probability of perfect health or immediate death is 
changed until the individual is indifferent between the health state and the 
gamble. 
Statistical significance: a conclusion that a technology has a true effect, 
based upon observed differences in outcomes between the treatment and control 
groups that are sufficiently large so that these differences are unlikely to have 
occurred due to chance, as determined by a statistical test. Statistical 
significance indicates the probability that the observed difference was due to 
chance if the null hypothesis is true; it does not provide information about the 
magnitude of a treatment effect. (Statistical significance is necessary but not 
sufficient for clinical significance.) 
Stratified analysis: a process of analysing smaller, more homogeneous 
subgroups according to specified criteria such as age groups, socioeconomic 
status, where there is variability (heterogeneity) in population. 
Subgroup: a defined set of individuals in a population group or of participants in 
a study such as subgroups defined by sex or age categories. 
Subgroup analysis: an analysis in which the intervention effect is evaluated in 
a subgroup of a trial, including the analysis of its complementary subgroup. 
Subgroup analyses can be pre-specified, in which case they are easier to 
interpret. If not pre-specified, they are difficult to interpret because they tend to 
uncover false positive results. 
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Surrogate endpoint: a measure that is used in place of a primary endpoint 
(outcome). Examples are decrease in blood pressure as a predictor of decrease 
in strokes and heart attacks in hypertensive patients, and increase in T-cell (a 
type of white blood cell) counts as an indicator of improved survival of patients 
with AIDS. Use of a surrogate endpoint assumes that it is a reliable predictor of 
the primary endpoint(s) of interest. 
Systematic review: a form of structure literature review that addresses a 
question that is formulated to be answered by analysis of evidence, and involves 
objective means of searching the literature, applying predetermined inclusion 
and exclusion criteria to this literature, critically appraising the relevant literature, 
and extraction and synthesis of data from evidence base to formulate findings. 
Technology: the application of scientific or other organised knowledge--
including any tool, technique, product, process, method, organisation or system--
to practical tasks. In healthcare, technology includes drugs; diagnostics, 
indicators and reagents; devices, equipment and supplies; medical and surgical 
procedures; support systems; and organisational and managerial systems used in 
prevention, screening, diagnosis, treatment and rehabilitation. 
Threshold analysis: type of sensitivity analysis in which model input is varied 
over a range to determine value of input that would lead to major changes in 
conclusions. 
Time horizon: the time span used in the assessment that captures the period 
over which meaningful differences between costs and outcomes between 
competing technologies would be expected to accrue. 
Time-to-event data or survival data: data that incorporates a measure of 
the time lapse before an event occurs, for example, time to relapse, time to 
death or time to treatment cessation. 
Time trade-off: a method of preference assessment used to measure utility. 
The utility value is measured by finding the point at which an individual is 
indifferent between two scenarios. That is, choices are provided to determine the 
length of time in an ideal health state that they would consider equivalent to a 
longer length of time with a specific condition. (Compare with standard gamble) 
Tornado diagram: diagrammatic display of the results of one-way sensitivity 
analysis; each bar represents the range of change in model results when the 
parameter is varied from its minimum to maximum values. 
Transferability: a trial, study or model has transportability if it can produce 
unbiased inferences to another specified healthcare system (e.g. from overseas 
to Ireland). 
Transfer (or income transfer) payment: payment made to individual 
(usually by government body) that does not perform any service in return; 
examples are social security payments and employment insurance benefits. 
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Uncertainty: where the true value of a parameter or the structure of a process 
is unknown. 
Usual care: this is the most common or most widely used alternative in clinical 
practice for a specific condition. This is also referred to as “routine care” or 
“current practice” or “typical care.” 
Utility: a measure of the relative desirability or preference (usually from the 
perspective of a patient) for a specific health outcome or level of health status 
compared to alternative health states. A numerical value is assigned on a 
cardinal scale of 0 (death) to 1 (optimal or ‘perfect’ health). Health states 
considered to be worse than death may be assigned a negative value. 
Validity: the extent to which technique measures what it is intended to 
measure. 
Valuation: the process of quantifying desirability of outcome in utility or 
monetary terms or of quantifying cost of resource or individual’s productivity in 
monetary terms. 
Value Added Tax: this is a tax on consumer spending. It is collected by VAT-
registered traders on their supplies of goods and services to customers. Each 
such trader in the chain of supply from manufacturer through to retailer charges 
VAT on his or her sales and is entitled to deduct from this amount the VAT paid 
on his or her purchases, that is, the tax is on the added value. For the final 
consumer, not being VAT-registered, VAT is simply part of the purchase price. 
Variability: this reflects known differences in parameter values arising out of 
inherent differences in circumstances or conditions. It may arise due to 
differences in patient population (e.g.  patient heterogeneity – baseline risk, age, 
gender), differences in clinical practice by treatment setting or geographical 
location. 
Willingness-to-pay (WTP): evaluation method used to determine maximum 
amount of money individual is willing to pay for particular outcome or benefit 
(e.g.  receive healthcare service); method is often used in cost-benefit analysis 
to quantify outcome in monetary terms. 
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